<SEC-DOCUMENT>0001601485-26-000035.txt : 20260429
<SEC-HEADER>0001601485-26-000035.hdr.sgml : 20260429
<ACCEPTANCE-DATETIME>20260429160617
ACCESSION NUMBER:		0001601485-26-000035
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260429
DATE AS OF CHANGE:		20260429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elicio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001601485
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113430072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39990
		FILM NUMBER:		26915891

	BUSINESS ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(857) 209-0050

	MAIL ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Angion Biomedica Corp.
		DATE OF NAME CHANGE:	20140228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>angn-20251231.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c4d80-2d30-72d4-8279-b11bd397a539,g:0cdb7a4b-5dfb-40da-9c45-c4c5792b6fa8,d:669fa5055ce74f1cb474bfb525237968-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:angn="http://www.angn.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-31">Nasdaq</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-true" id="f-32">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-33">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001601485</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-09</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i669fa5055ce74f1cb474bfb525237968_37"></div><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:112%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:112%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">_______________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:112%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K/A</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">(Amendment No. 1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">_______________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric>           ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">December&#160;31, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">Or</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric>           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">For the transition period from _________ to ________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39990</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">___________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ELICIO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">___________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"/><td style="width:44.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.779%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">11-3430072</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">451 D Street, 5th Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02210</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(Zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">209-0050</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"/><td style="width:33.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.811%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Trading<br/>symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.01</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">ELTX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">______________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  &#9744;    <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-18">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  &#9744;  <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-19">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-20">Yes</ix:nonNumeric>  &#9746;  No  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-21">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.048%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Large accelerated filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Accelerated filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-22">Non-accelerated filer</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Smaller reporting company </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-23">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Emerging growth company </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  &#9744;    <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">aggregate market value of the voting stock and non-voting common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#8217;s common stock on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">June&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> as reported by the Nasdaq Capital Market on such date, was approximately </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" scale="6" id="f-29">81.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">. Shares of common stock held by each executive officer and director and by each entity affiliated with an executive officer or director have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The number </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">of shares of the registrant&#8217;s common stock outstanding as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">April&#160;9, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> was</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">18,704,798</ix:nonFraction>.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i669fa5055ce74f1cb474bfb525237968_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">EXPLANATORY NOTE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:AmendmentDescription" id="f-37" continuedAt="f-37-1">This Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) amends the Annual Report on Form 10-K of Elicio Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;Elicio&#8221;) for the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-38">December&#160;31, 2025</ix:nonNumeric>, as originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;12, 2026 (the &#8220;Original 10-K&#8221;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-37-1">Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company&#8217;s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. As used in this Amendment, unless otherwise stated or the context otherwise indicates, references to &#8220;Elicio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Elicio Therapeutics, Inc. and our wholly owned subsidiaries following Elicio&#8217;s reverse merger transaction (the &#8220;Merger&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;) that was completed on June 1, 2023. Terms used but not defined herein shall have the meaning ascribed to them in the Original 10-K.</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_200"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Amendment contains forward-looking statements within the meaning of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Private Securities Litigation Reform Act of 1995. All statements contained in this Amendment other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 7P and any other current or future product candidates, our ability to continue as a going concern and our cash runway;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in oncology and other disease areas;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, progress and results of clinical trials for ELI-002 7P, and other current or future product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available, and the timing, progress and results of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications and U.S. Food and Drug Administration approval of ELI-002 7P and any current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our manufacturing, commercialization, marketing capabilities, strategy and associated timelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expectations regarding the approval and use of our product candidates in combination with other drugs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expectations regarding potential for accelerated approval or other expedited regulatory designation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our competitive position and the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our anticipated research and development activities and projected expenditures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, Europe and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the extent to which global economic and political developments, including the ongoing conflict between Ukraine and Russia, the conflicts in the Middle East, including the conflict between Israel and Palestine and the conflict between Israel and Iran, geopolitical tensions with China, and other geopolitical events, as well as the macroeconomic conditions, including tariffs, inflation, volatility in interest rates, potential for economic slowdown or recession and potential government shutdowns, will affect our business operations, clinical trials, or financial condition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding other macroeconomic trends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ELI-002 7P, other current or future product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to have manufactured sufficient supplies of drug product for clinical testing and commercialization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our projected financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our anticipated use of proceeds from potential financing activities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential impact of anticipated funding pressures and the expected effect from U.S. export controls and tariffs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Amendment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in the &#8220;Risk Factors&#8221; section in Part I, Item 1A of the Original 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and are based on assumptions as of the date of this Amendment. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Amendment. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Amendment also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_87"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">ELICIO THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">FORM 10-K/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">TABLE OF CONTENTS</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:91.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">PART III</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_112">Item 10.  Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_112">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_120">Item 11.  Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_120">16</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_129">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_129">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_137">Item 13.  Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_137">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_145">Item 14.  Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_145">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">PART IV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_162">Item 15.  Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_162">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_171">Item 16.  Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_171">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_179">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_179">31</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_95"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Board of Directors and Executive Officers</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information regarding our executive officers and directors as of April&#160;9, 2026:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert Connelly</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Strategy and Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Haqq, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Head of Research and Development and Chief Medical Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Peter DeMuth, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Non-Employee Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Julian Adams, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chair of Board of Directors (the "Board of Directors" or the "Board") and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carol Ashe</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Allen Nissenson, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Yekaterina (Katie) Chudnovsky</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert R. Ruffolo, Jr., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Karen Wilson</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jay Venkatesan, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of our Audit Committee. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of our Compensation Committee. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of our Nominating and Corporate Governance Committee. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Each of our directors holds office until the next annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Executive Officers</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Robert Connelly</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as Elicio&#8217;s Chief Executive Officer and President and as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as Chief Executive Officer of Elicio Operating Company, Inc. (&#8220;Former Elicio&#8221;) and as a member of Former Elicio&#8217;s Board of Directors from October 2018 until the Merger. Mr. Connelly has 31 years of leadership experience in the life sciences sector with over 25 years of experience as chief executive officer. From 2013 to 2018, Mr. Connelly served as the Chief Executive Officer and as a member of the board of directors of Axcella Health Inc., a clinical-stage therapeutics company developing endogenous metabolic modulators to treat an array of diseases. Prior to Axcella, Mr. Connelly served as the founding Chief Executive Officer of WikiCell Designs and the Chairman of Aero Designs, each utilizing drug delivery technologies to create new food, beverage and supplement products, both of which merged into Incredible Foods, Inc. in 2013. Prior to that, Mr. Connelly served as the Chief Executive Officer of Pulmatrix, Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to address pulmonary diseases, from 2007 to 2012. From 2000 to 2007, Mr. Connelly served as the founding Chief Executive Officer and first employee of Domantis Ltd., a U.K.-based biotechnology company, which was acquired by GSK plc. He began his career with life science companies Abbott Laboratories and BioVeris Corporation in positions of increasing responsibility. Mr. Connelly previously served on the boards of publicly traded life science companies Kaleido Biosciences, Inc. from 2015 to 2018 and Anchiano Therapeutics Ltd. from 2018 to 2019, as well as on the boards of several privately held biopharmaceutical companies. Mr. Connelly also served as a Venture Partner with Flagship Pioneering from 2013 to 2018, working on the creation and management of several biotechnology portfolio companies. Mr. Connelly received a B.S. in Business Administration from the University of Florida.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Mr. Connelly is qualified to serve as a director based on his role as our Chief Executive Officer and President and his extensive management experience in the life sciences industry.     </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preetam Shah, Ph.D. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as Elicio&#8217;s Chief Strategy and Financial Officer and Treasurer since March 2025. He previously served as Chief Financial Officer and Chief Business Officer of Cidara Therapeutics, Inc., a publicly traded biotechnology company, from September 2021 to August 2024 and Chief Financial Officer and Principal Accounting Officer from August 2024 to February 2025. Prior to that, Dr. Shah served as Executive Vice President, Chief Financial Officer and Treasurer at Brainstorm Cell Therapeutics, Inc. (&#8220;Brainstorm&#8221;), a publicly traded biotechnology company, from September 2019 to August 2021. Prior to Brainstorm, Dr. Shah spent over six years as an investment banker advising healthcare companies on equity, debt and M&amp;A transactions; holding senior roles at banks, including Barclays Capital PLC., from June 2016 to September 2019, and Canaccord Genuity Inc., from July 2013 to May 2016. From 2010 to 2013, Dr. Shah founded Saisarva LLC, a healthcare consulting firm. During this period, he also acted as a consultant for healthcare-focused private equity firms and hedge funds. From 2006 to 2009, Dr. Shah served as Vice President, U.S. Operations and Investments at Reliance Capital USA Ventures LLC, an affiliate of Reliance ADA Group Companies, where he was responsible for making early-stage venture investments in healthcare companies. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine. He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center, an M.B.A. in Finance from the Wharton School, University of Pennsylvania, and a B.A. in Mathematics and in Biology from McDaniel College.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Christopher Haqq, M.D., Ph.D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">. has served as Elicio&#8217;s Executive Vice President, Head of Research and Development and Chief Medical Officer since June 2023 and previously served as Former Elicio&#8217;s Executive Vice President, Head of Research and Development and Chief Medical Officer from October 2019 until the Merger. Dr. Haqq brings over 20 years of drug development leadership experience at both large and small biotechnology companies. From February 2017 to October 2019, Dr. Haqq served as the Executive Vice President, Research and Development and Chief Scientific Officer of Atara Biotherapeutics, Inc., a biotechnology company focused on T-cell immunotherapy including Ebvallo&#174;, where he previously served as the first Chief Medical Officer from 2012 to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">2017. From 2007 to 2011, Dr. Haqq was the lead medical monitor for the pivotal trial leading to marketing approval for Zytiga&#174; at Cougar Biotechnology, Inc., a cancer-focused biotechnology company that was acquired by Johnson &amp; Johnson in 2009. Prior to that time, Dr. Haqq served in drug development roles at Amgen Inc., a biotechnology company, and practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. From July 2019 to July 2022, Dr. Haqq served on the board of a privately held real estate rental company. From November 2020 to April 2021, he served as a director of Consonance-HFW Acquisition Corp. Dr. Haqq received a B.S. from Stanford University and an M.D. and a Ph.D. from Harvard Medical School.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">     </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Peter DeMuth, Ph.D.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as Elicio&#8217;s Chief Scientific Officer since June 2023 and previously served as Former Elicio&#8217;s Chief Scientific Officer from January 2022 until the Merger. Dr. DeMuth brings over 15 years of biotechnology experience in oncology, immunology and materials science. From June 2013 to August 2017, Dr. DeMuth served as a Scientist at Former Elicio. In late 2017, Dr. DeMuth began to hold roles of increasing responsibility at Former Elicio, where he served as Director of Research from August 2017 to November 2018, and then as Vice President of Research from November 2018 to January 2022. Prior to joining Former Elicio, Dr. DeMuth oversaw efforts to develop novel technologies for vaccine delivery at the Massachusetts Institute of Technology&#8217;s (&#8220;MIT&#8221;) Koch Institute for Integrative Cancer Research in affiliation with the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University, where he received recognition from the National Science Foundation, the American Chemical Society, and the Thomas and Stacy Siebel Foundation. In 2015, Dr. DeMuth received the Quadrant Award from Quadrant AG, a global manufacturer and innovator in polymer materials science, for research he completed while at the Koch Institute at MIT. Dr. DeMuth has also been an NIH Fellow at the Whitehead Institute for Biomedical Research and a research fellow at Novartis Vaccines and Diagnostics. As a Howard Hughes Research Fellow at the University of Maryland, he was awarded the University Medal for his development of advanced technologies for oncology therapeutics. In 2024, Dr. DeMuth was named in PharmaVoice 100s: Trailblazers and was named in the 40 Under 40 in Cancer. Dr. DeMuth received a B.S. in Chemical Engineering and B.S. in Biochemistry from the University of Maryland, College Park and a Ph.D. in Biological Engineering from MIT. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Non-Employee Directors </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Julian Adams, Ph.D.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as Chair of Elicio&#8217;s Board of Directors since June 2023 and previously served as Chair of Former Elicio&#8217;s Board of Directors from 2017 until the Merger. Dr. Adams currently serves as President and Chief Executive Officer of Stand Up To Cancer, a charitable program of the Entertainment Industry Foundation, a role he has held since January 2024. In July 2023, Dr. Adams joined Stand Up To Cancer as its first Chief Science Officer.  Dr. Adams was previously the Chief Executive Officer of Gamida Cell Ltd., a clinical-stage biopharmaceutical company working to develop cell therapies for hematologic cancers and rare, serious hematologic diseases, from November 2018 to October 2022. Prior to Gamida Cell, Dr. Adams was President and Chief Scientific Officer at Clal Biotechnology Industries Ltd. (&#8220;CBI&#8221;) from January 2017 to November 2017. Before joining CBI, Dr. Adams served as President of Research and Development at Infinity Pharmaceuticals, Inc. from 2003 to 2017, and also as its Chief Scientific Officer from 2006 to 2010 where he built and led the company&#8217;s R&amp;D efforts. From 1999 to 2003, Dr. Adams served as Senior Vice President, Drug Discovery and Development at Millennium Pharmaceuticals, Inc., now part of Takeda Pharmaceutical Company Limited, where he played a key role in the discovery of Velcade&#174; (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma. Earlier in his career, Dr. Adams was credited with discovering Viramune&#174; (nevirapine) for HIV at Boehringer Ingelheim. Dr. Adams has also held senior leadership roles in research and development at LeukoSite, Inc. and ProScript. Dr. Adams previously served on the board of Pieris Pharmaceuticals, Inc. from 2016 to 2018 and Neon Therapeutics, Inc., now BioNTech SE from 2017 to 2018. Dr. Adams currently serves as a director for Gamida Cell Ltd., a private company developing cell and immune therapy technology, and Immunyx, a private drug development company pioneering approaches to immune modulation. Dr. Adams earned a B.S. from McGill University, where he also was awarded an honorary Sc.D, and a Ph.D. from the Massachusetts Institute of Technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Dr.&#8239;Adams is qualified to serve as a director based on his extensive science background and professional experience. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Carol Ashe </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as a member of Former Elicio&#8217;s Board of Directors from August 2020 until the Merger. Previously, Ms. Ashe was the Chief Business Officer at the New York Genome Center, an independent, non-profit academic research institution focused on the advancement of genomic science, from 2014 until 2025. From 2011 to 2013, Ms. Ashe served as Vice President of Corporate Development for Endo&#8217;s branded, generic and platform drug delivery pharmaceutical </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">business units.  She also served as a Partner at SR One, when it was the corporate venture capital fund of GSK plc (&#8220;GSK&#8221;) from 2008 to 2010; and head of GSK&#8217;s US Corporate Legal Group supporting US-based mergers, acquisitions, and equity investments from 2007 to 2008. Prior to that, Ms. Ashe led GSK&#8217;s global Business Development Transactions Legal Team supporting both the pharmaceutical and consumer healthcare business units for many years until 2007. In addition, Ms. Ashe served on the board of Aptose Biosciences, a clinical stage biotechnology company addressing unmet clinical needs in oncology from 2018 to 2025. Ms. Ashe received a B.S. in Biology from Pennsylvania State University, a J.D. from Villanova University School of Law and is a registered patent attorney. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Ms.&#8239;Ashe is qualified to serve as a director due to her extensive experience in the pharmaceutical biotechnology industry in business development and as legal counsel for business development transactions and patent matters.     </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Allen R. Nissenson, M.D.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as a member of Angion&#8217;s Board of Directors from January 2020 until the Merger. Dr. Nissenson completed serving as the Emeritus Chief Medical Officer of DaVita Kidney Care in January 2022, where he had served since January 2020 and where he previously served as Chief Medical Officer from August 2008 to January 2020. Dr. Nissenson is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA, where he has served since August 2008, and where he previously served as Director of the Dialysis Program from July 1977 to August 2008 and Associate Dean from July 2005 to August 2008. Dr. Nissenson is also currently on the board of directors of Rockwell Medical, Inc., a public biopharmaceutical company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products for dialysis providers, which he joined in June 2020, Diality, Inc., a private technology development company, and Innocura Nephology, Inc., a privately-held company. Dr. Nissenson is a past chair of Kidney Care Partners and past co-chair of the Kidney Care Quality Alliance. Dr. Nissenson is a former president of the Renal Physicians Association (&#8220;RPA&#8221;) and current member of the RPA&#8217;s Government Affairs Committee. Dr. Nissenson previously served as president of the Southern California End-Stage Renal Disease Network, as well as the chair of its Medical Review Board. Dr. Nissenson served as a Robert Wood Johnson Health Policy Fellow of the National Academy of Medicine from 1994 to 1995 and worked in the office of the late Senator Paul Wellstone. Dr. Nissenson has an M.D. from Northwestern University Medical School and is the recipient of various awards, including the President&#8217;s Award of the National Kidney Foundation, the Lifetime Achievement Award in Hemodialysis, the American Association of Kidney Patients&#8217; (&#8220;AAKP&#8221;) Medal of Excellence Award and, in 2017, the RPA Distinguished Nephrology Service Award. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Dr. Nissenson is qualified to serve as a director due to his years of experience in the healthcare industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Yekaterina (Katie) Chudnovsky</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as a member of Former Elicio&#8217;s Board of Directors from October 2022 until the Merger. Ms. Chudnovsky is an attorney, venture investor, dedicated patient advocate, and supporter of medical research, with particular interest in cancer research and personalized cancer vaccines. Ms. Chudnovsky is Chairperson of the GI Research Foundation for the University of Chicago Digestive Diseases Center (&#8220;GI Research Foundation&#8221;), where she has sat on the board for the past 14 years, becoming President in 2019 and Chairperson in 2023. She is an active board member of xCures, Inc., a privately-held technology company working to advance cancer research and patient outcomes with an AI-based precision oncology platform and also currently serves as director at GKCC, LLC, a privately-held company, Immix Biopharma, Inc., a public company, Colorectal Cancer Alliance, a non-profit organization focused on colorectal cancer, and serves as a board observer for MiNK Therapeutics, Inc., a public, clinical-stage biopharmaceutical company. Prior to Ms. Chudnovsky&#8217;s current roles, she began her legal career at Thomas Coburn LLP with a focus on corporate law, real estate, mergers and acquisitions, bankruptcy, and business banking. Ms. Chudnovsky received a B.A. in political science and Slavic literature and language from Northwestern University and a J.D. from DePaul University.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Ms. Chudnovsky is qualified to serve as a director due to her experience in the healthcare industry and her legal background. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Robert R. Ruffolo, Jr., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as a member of Former Elicio&#8217;s Board of Directors from 2018 until the Merger. Dr. Ruffolo has operated and been a Managing Director at Ruffolo Consulting, LLC, a consulting firm advising large pharmaceutical and biotechnology companies, since 2008. Previously, Dr. Ruffolo served as President of Research and Development and as Corporate Senior Vice President of Wyeth Pharmaceuticals Inc. (now Pfizer Inc.) from 2002 to 2008. From 2000 to 2002, Dr. Ruffolo served as an Executive Vice President at Wyeth Pharmaceuticals, where he was </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">responsible for Pharmaceutical Research and Development. Prior to joining Wyeth Pharmaceuticals, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc (now GSK plc) where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline Beecham Pharmaceuticals plc, Dr. Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984 where he was Chairman of the Cardiovascular Research Committee. Dr. Ruffolo currently serves on the boards of several private companies. He received a B.S. in Pharmacy and a Ph.D. in Pharmacology from The Ohio State University.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Dr. Ruffolo is qualified to serve as a director due to his extensive experience in the pharmaceutical industry and his technical and management expertise in product discovery and development.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Karen Wilson</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of Elicio's Board of Directors since June 2023 and previously served as a member of Angion's Board of Directors since April 2020 until the Merger. Ms. Wilson has also been a board member of Connect Biopharma Holdings Ltd., a public company focused on improving the lives of patients living with chronic inflammatory diseases, since 2020, and Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology, since 2025. Ms. Wilson also served as a member of the board of directors of LAVA Therapeutics B.V, a public company, from 2021 to 2025 (acquired) and Vaxart, Inc., a public company, from 2020 to 2022. Ms. Wilson previously served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a biopharmaceutical company, until September 2020 after serving as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. Ms. Wilson also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte &amp; Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Ms. Wilson is qualified to serve as a director due to her extensive background in financial and accounting matters for public companies and her leadership experience in the life science industry. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Jay Venkatesan, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of Elicio&#8217;s Board of Directors since June 2023 and previously served as Chairman of Angion&#8217;s Board of Directors from January 2022 until the Merger. From May 2018 to June 2023, Dr. Venkatesan served as Angion&#8217;s President and Chief Executive Officer. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm since July 2015. From July 2015 to August 2018, Dr. Venkatesan was Co-Founder and President of Alpine Immune Sciences, Inc., an immunotherapy company acquired by Vertex Pharmaceuticals in May 2024, and served as its Chief Executive Officer from July 2015 to June 2016. Additionally, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, Inc., a biotechnology company, which was acquired by Cascadian Therapeutics, Inc. From January 2008 to July 2015, Dr. Venkatesan served as the Founder and Managing Member of Ayer Capital, a global healthcare investment fund. Prior to that, Dr. Venkatesan served for six years as a director at Brookside Capital, the hedge fund subsidiary of Bain Capital, where he co-managed healthcare investments. Dr. Venkatesan was also a consultant at McKinsey &amp; Company, a consulting firm, and a venture investor with Apax Partners, an investment firm. Since 2018, Dr. Venkatesan has served on the board of Zylem Biosciences, Inc., a private biotechnology company. Since March 2025, Dr. Venkatesan has served on the board and as Chairman of the Nominating and Corporate Governance Committee of Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology. Dr. Venkatesan previously served on the board of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated) from June 2015 to July 2022, Iovance Biotherapeutics Inc. from 2013 to 2018, and Cell Biotherapies, Inc. from 2015 until its acquisition by Vaxanix Bio, Ltd. in 2023. Dr. Venkatesan has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. from Williams College. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors believes that Dr.&#8239;Venkatesan is qualified to serve as a director based on his experience serving in leadership positions in biotechnology companies, as well as the operational expertise and continuity that he brings to our Board of Directors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Director Independence</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As required under the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. In addition, the Nasdaq listing standards require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation, and nominating and corporate governance committee must be independent under the Exchange Act. Under Rule 5605(a)(2) of the Nasdaq listing standards, a director will only qualify as an </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;independent director&#8221; if, in the opinion of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Compensation committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. In order to be considered independent for purposes of Rule 10C-1, a board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors consults with our counsel to ensure that their determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and Elicio, our senior management and our independent auditors, the Board of Directors has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">listing standards: Dr. Julian Adams, Ms. Carol Ashe, Dr. Robert R. Ruffolo, Jr., Ms. Karen Wilson and Dr. Allen Nissenson. In making this determination, the Board of Directors found that none of these directors had a material or other disqualifying relationship with Elicio. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Jay Venkatesan is not considered independent because he was an executive officer of Angion within the past three years. Mr. Robert Connelly is not considered independent because he is an executive officer of Elicio.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Ms. Yekaterina (Katie) Chudnovsky is not considered independent because of her significant ownership of Elicio&#8217;s securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, as required by Nasdaq rules, our Board of Directors has made a subjective determination as to each independent director that no relationships exist that, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Familial Relationships </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">There are no family relationships among any of our directors or executive officers.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Board Leadership Structure </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Elicio&#8217;s Board of Directors is currently chaired by Dr. Julian Adams.    </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors has the flexibility to combine or separate the positions of Chairperson of the Board of Directors and Chief Executive Officer and/or to implement the role of Lead Independent Director in accordance with its determination that utilizing one or the other structure would be in the best interests of our Company. Our current Board of Directors leadership structure separates the positions of Chief Executive Officer and Board Chair. The Board of Directors believes that this separation is appropriate for the organization at this time because it allows for a division of responsibilities and the sharing of ideas between individuals having different perspectives. Our Chief Executive Officer, who is also a member of our Board of Directors, is primarily responsible for our day-to-day operations and strategic direction, while our Chair of the Board of Directors, who is an independent member of the Board of Directors, is primarily focused on matters pertaining to corporate governance, including management oversight. While the Board of Directors believes that this is the most appropriate structure at this time, the Board of Directors retains the authority to change the Board of Directors structure, including the possibility of combining the Chief Executive Officer and Chairperson of the Board of Directors position, if it deems such a change to be appropriate in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Role of the Board in Risk Oversight </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Risk assessment and oversight are an integral part of our governance and management processes. Our Board of Directors encourages management to promote a culture incorporating risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions during the year including a focused discussion and analysis of the risks we may face. Throughout the year, senior management reviews these risks with the Board of Directors at regular Board of Directors meetings as part of management presentations focusing on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors does not have a standing risk management committee, but rather administers this oversight function directly through our Board of Directors as a whole, as well as through various standing committees of our Board of Directors addressing risks inherent in their respective areas of oversight.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors may delegate to the Audit Committee oversight of our risk management process. Our other committees will also consider and address risk as they perform their respective committee responsibilities. Specifically, the Audit Committee receives periodic reports from members of senior management on areas of material risk to us, including operational, financial, and legal risks, and risks related to IT and cyber security. Our Audit Committee periodically discusses with management our major risk exposures, their potential financial impact on us and the steps we take to manage them. Our Compensation Committee assists the Board of Directors in fulfilling its oversight responsibilities with respect to the management of risks arising from our compensation policies and programs. Our Nominating and Corporate Governance Committee assists the Board of Directors in fulfilling its oversight responsibilities with respect to the management of risks associated with the Board of Directors organization, membership and structure, succession planning for our directors and executive officers and corporate governance. All committees report to the full Board of Directors as appropriate, including when a matter rises to the level of a material or enterprise level risk.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Meetings of the Board of Directors </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to our Corporate Governance Guidelines, each director is expected to spend the time and effort necessary to properly discharge his or her responsibilities and is expected to regularly prepare for and attend meetings of the Board of Directors and all committees on which the director sits, with the understanding that, on occasion, a director may be unable to attend a meeting. A director who is unable to attend a meeting of the Board of Directors or a committee is expected to notify the Chair of the Board of Directors or the Chair of the appropriate committee in advance of such meeting, and whenever possible, participate in such meeting via teleconference in the case of an in-person meeting.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Information Regarding Committees of the Board of Directors </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Each of these committees operates under a charter that has been approved by our Board of Directors and members will serve on these committees until their resignation or as otherwise determined by our Board of Directors. Below is a description of each committee of the Board of Directors.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board of Directors has determined each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to Elicio.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee of the Board of Directors was established by the Board of Directors in accordance with Section 3(a)(58)(A) of the Exchange Act, to oversee Elicio&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions, including among other things:   </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">appointing, engaging, compensating, retaining, and overseeing the work of any independent auditor;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">assessing the independence of our independent auditor; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">pre-approving all audit and non-audit services to be performed by our independent auditor; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing our financial statements and related disclosures; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing the adequacy and effectiveness of our accounting and financial reporting processes, systems of internal control over financial reporting and disclosure controls and procedures and code of conduct; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing and discussing with management our overall risk assessment and risk management framework; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">establishing procedures for the receipt, retention and treatment of complaints on accounting, internal accounting controls, or auditing matters; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing and discussing with management and our independent auditor the results of our annual audit, our quarterly financial statements and our publicly filed reports; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">coordinating the evaluation of our financial management personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">consulting with management to establish procedures and internal controls relating to cybersecurity risk management, strategy and governance; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing and approving related person transactions; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">preparing the audit committee report that the SEC requires in our annual proxy statement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee is composed of Karen Wilson, Allen Nissenson, M.D., and Carol Ashe. Ms. Wilson serves as the chairperson of the Audit Committee. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our Board of Directors has determined Ms. Wilson is an &#8220;audit committee financial expert&#8221; as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Our Board of Directors has determined that each of Ms. Wilson, Dr. Nissenson, and Ms. Ashe are independent under the applicable rules of the SEC and Nasdaq.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-39">December&#160;31, 2025</ix:nonNumeric>, our Audit Committee met five times. The Board of Directors has adopted a written Audit Committee charter available to stockholders</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">on our website. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Compensation Committee </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee is composed of Carol Ashe, Allen Nissenson, M.D., and Robert R. Ruffolo, Jr., Ph.D. Ms. Ashe serves as the chairperson of the Compensation Committee. Each of the members of our Compensation Committee is independent under the applicable rules and regulations of Nasdaq and is a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act. During the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-40">December&#160;31, 2025</ix:nonNumeric>, Elicio&#8217;s Compensation Committee met three times. The Board of Directors has adopted a written Compensation Committee charter available to stockholders on Elicio&#8217;s website. Our Compensation Committee&#8217;s role and responsibilities set forth in the Charter include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing, approving and making recommendations regarding our compensation policies, along with conducting periodic reviews of the adequacy of Elicio&#8217;s compensation programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing, approving and making recommendations regarding corporate goals and objectives relevant to the compensation of our executive officers (other than Elicio&#8217;s Chief Executive Officer), evaluating the performance of these executive officers in light of those goals and objectives and approving the compensation of these executive officers based on such evaluations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">retaining, and if need be, replacing any compensation or benefits consultants or other outside experts or advisors the Compensation Committee believes is necessary; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overseeing compliance of Elicio&#8217;s equity compensation plans and, subject to stockholder approval, exercising administrative responsibility over such plans, including, reviewing, approving and making recommendations regarding the issuance of stock options and other awards under our stock plans to our executive officers (other than our Chief Executive Officer);  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">determining our policies with respect to change of control or &#8220;parachute&#8221; payments;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing and making recommendations to our Board of Directors regarding director compensation; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">reviewing and recommending to our Board of Directors for approval, the compensation of our Chief Executive Officer, conducting this decision-making process without the Chief Executive Officer present. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In establishing compensation amounts for executives, the Compensation Committee seeks to provide compensation that is competitive in light of current market conditions and industry practices. Accordingly, the Compensation Committee will generally review market data which is comprised of proxy disclosed data from peer companies and information from nationally recognized published surveys for the biopharmaceutical industry. The market data helps the Compensation Committee gain perspective on the compensation levels and practices at peer companies and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">allows the Compensation Committee to assess the relative competitiveness of the compensation paid to our executives. The market data thus guides the Compensation Committee in its efforts to set executive compensation levels and program targets at competitive levels for comparable roles in the marketplace. The Compensation Committee then considers other factors, such as the importance of each executive officer&#8217;s role to the Company, individual expertise, experience, and performance, retention concerns and relevant compensation trends in the marketplace, in making its final compensation determinations. From time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. Periodically, the Compensation Committee will review and evaluate the performance of the Compensation Committee and its members, including compliance by the Compensation Committee with its charter.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of Elicio, advice and assistance from compensation consultants, benefits consultants, independent legal counsel, or other advisors and other external resources the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, external legal counsel or other adviser to the Compensation Committee only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the past fiscal year,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">after taking into consideration the six factors prescribed by the SEC and Nasdaq described above, the Compensation Committee engaged Aon plc</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;Aon&#8221;) as its compensation consultant. The Compensation Committee requested that Aon: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">evaluate the efficacy of Elicio&#8217;s existing compensation strategy and practices in supporting and reinforcing our long-term strategic goals;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">assist in refining our compensation strategy and in developing and implementing an executive compensation program to execute that strategy;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">assist in defining the appropriate market of our peer companies for executive compensation and practices and in benchmarking our executive compensation program against the peer group each year; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">assist the Compensation Committee in benchmarking our director compensation program and practices against those of our peers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Aon performs services on behalf of the Compensation Committee, relating to compensation consulting services. The Compensation Committee has authorized Aon to interact with management on behalf of the Compensation Committee, as needed in connection with advising and providing such compensation consulting services to the Compensation Committee, and Aon is included in discussions with management and, when applicable, the Compensation Committee&#8217;s outside legal counsel on matters being brought to the Compensation Committee for consideration.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors, at the recommendation of our Compensation Committee, has also delegated to our Chief Executive Officer the authority to determine and approve the equity compensation payable to Elicio&#8217;s employees and consultants who are not &#8220;officers&#8221; (as defined in Section 16 of the Exchange Act) and who hold positions of Vice President and below.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Nominating and Corporate Governance Committee</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Nominating and Corporate Governance Committee is composed of Julian Adams, Ph.D., Carol Ashe, and Karen Wilson. Dr. Adams serves as the chairperson of the Nominating and Corporate Governance Committee. Each of Julian Adams, Ph.D., Carol Ashe and Karen Wilson is independent under the applicable rules and regulations of Nasdaq relating to nominating and corporate governance committee independence. During the fiscal year ended  <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-41">December&#160;31, 2025</ix:nonNumeric>, the Nominating and Corporate Governance Committee met two times. The Board of Directors has adopted a written Nominating and Corporate Governance Committee charter available to stockholders on our website and our Nominating and Corporate Governance Committee&#8217;s role and responsibilities set forth in the charter include, among other things:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">evaluating and making recommendations to the Board of Directors regarding candidates for directorships and the size and composition of our Board of Directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overseeing our corporate governance policies, including developing and recommending Elicio&#8217;s Corporate Governance Guidelines to the Board of Directors, and reporting and making recommendations to our Board of Directors concerning governance matters, including, but not limited to our Amended and Restated Certificate of Incorporation, as amended, Amended and Restated Bylaws, and the charters of our other committees;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overseeing and administering the performance evaluation process of the Board of Directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintaining oversight of matters relating to independence of the Board of Directors and Committee members; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">overseeing Elicio&#8217;s environmental, social and governance strategy, initiatives and policies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">evaluating the Company&#8217;s executive officer succession plans (other than the Chief Executive Officer); and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">assessing and overseeing the effectiveness of the relationship between the Board of Directors and Elicio&#8217;s management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Nominating and Corporate Governance Committee believes candidates for director should have certain minimum qualifications, including having the highest personal and professional integrity, strong ethics and values and the ability to make mature business judgments. The Nominating and Corporate Governance Committee also considers such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of Elicio, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of Elicio&#8217;s stockholders. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board of Directors, the operating requirements of Elicio and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, skills and such other factors as it deems appropriate, given the current needs of the Board of Directors and Elicio, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board of Directors. The Nominating and Corporate Governance Committee takes into account the results of the Board of Directors&#8217; self-evaluation, conducted on a periodic basis, on a group and individual basis. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. Then, the Nominating and Corporate Governance Committee uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board of Directors. In addition, the Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then selects a nominee for recommendation to the Board of Directors by majority vote.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Policy Regarding Consideration of Director Candidates Recommended by Stockholders</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Nominating and Corporate Governance Committee has adopted a policy regarding consideration of director candidates recommended by stockholders. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board of Directors may do so by delivering a written recommendation to the Corporate Secretary at Elicio Therapeutics, Inc., 451 D Street, Suite 501, Boston, MA 02210, in accordance with the procedures described in our Amended and Restated Bylaws. Written recommendations must include the following information: name and address of the nominating stockholder; a representation that the nominating stockholder is a record holder; a representation that the nominating stockholder intends to appear in person or by proxy at the Company&#8217;s annual stockholders&#8217; meeting to nominate the person or persons specified; information regarding each nominee that would be required to be included in a proxy statement; a description of any arrangements or understandings between the nominating stockholder and the nominee; and the consent of each nominee to serve as a director, if elected. The Nominating and Corporate Governance Committee will evaluate candidates recommended by a stockholder in the same manner as candidates identified by the Board of Directors. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Communications with the Board of Directors </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Generally, stockholders who have questions or concerns should contact Elicio's Investor Relations department at IR@elicio.com. However, any stockholders who wish to address questions regarding our business directly with the Board, or any individual director, should direct their questions in writing to the Chairperson of the Board of Directors at 451 D Street, Suite 501, Boston, MA 02210. Elicio will make every effort to ensure that communications are distributed to the Board of Directors, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications, and that appropriate responses are provided to stockholders in a timely manner. Elicio believes its responsiveness to stockholder communications to the Board of Directors is excellent. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as junk mail and mass mailings, resumes and other forms of job inquiries, surveys, and solicitations or advertisements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Code of Business Conduct and Ethics </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Elicio has adopted the Elicio Code of Business Conduct and Ethics applying to all officers, directors, employees, and consultants. The Code of Business Conduct and Ethics is available on Elicio&#8217;s website. If Elicio makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code to any executive officer or director, Elicio will promptly disclose the nature of the amendment or waiver on its website. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Corporate Governance Guidelines </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In June 2023, the Board of Directors, following the Merger, adopted Angion&#8217;s Corporate Governance Guidelines, as subsequently amended from time to time,  to assure the Board of Directors will have the necessary authority and practices in place to review and evaluate Elicio&#8217;s business operations as needed and to make decisions that are independent of Elicio&#8217;s management. The guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate Governance Guidelines set forth the practices the Board of Directors intend to follow with respect to Board composition and selection, Board meetings and involvement of senior management, and Board committees and compensation. The Corporate Governance Guidelines may be viewed on our website.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Insider Trading Policy and Procedures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have an insider trading compliance policy that, among other things, governs the buying and selling of our securities by all of our personnel, including directors, officers, employees and consultants and certain other covered persons. Our policy is designed to prevent violations of insider trading laws by our personnel and to avoid even the appearance of improper conduct in this regard by our personnel. The policy prohibits covered persons from purchasing or selling our securities while in possession of material non-public information (except in limited circumstances, such as pursuant to a previously established trading plan). In addition, the policy prohibits all employees (including officers and directors) and consultants from engaging in any transaction in which they may profit from short-term speculative swings in the value of our securities, including any of the following activities: (1) &#8220;short sales&#8221; (selling borrowed securities that the seller hopes can be purchased at a lower price in the future) of our securities; (2) purchasing our securities on margin or using our securities to secure margin or other loans; (3) transactions in our securities involving certain forms of hedging or monetization transactions such as zero-cost collars and forward sales contracts; and (4) transactions in publicly traded options relating to our securities (i.e., options that are not granted by us). The policy includes quarterly and other trading blackouts and sets forth the procedures covered persons must follow before transacting in our securities, including pre-clearance by our Compliance Officer, or in their absence, our Chief Financial Officer, of all transactions by executive officers and directors and certain employees and consultants, as well as members of their households. A copy of our insider trading compliance policy is filed as an exhibit to the Original 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The insider trading compliance policy described above applies to transactions by our directors, officers, employees, consultants, and other covered persons. We have not, however, adopted a separate insider trading policy governing the purchase, sale, and/or other disposition of our securities by the Company itself. As part of the oversight of risk, the Board of Directors, or one or more of its Committees, approves any transaction, plan or arrangement by or with the Company with respect to our securities on a case-by-case basis, and as part of their procedures to review and approve any such transaction, plan or arrangement, the Board of Directors or Committee consults with legal counsel to ensure compliance with applicable insider trading laws, rules and regulations, and listing standards. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Clawback Policy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In October 2023, our Board of Directors adopted a Clawback Policy to comply with the new clawback rules and listing standards promulgated by the SEC and Nasdaq, respectively. The Clawback Policy generally provides that we will seek to recover, in the event of a required accounting restatement, excess incentive compensation received by covered officers where that compensation is based on erroneously reported financial information, regardless of fault or misconduct.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_120"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 11. Executive Compensation.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Executive Officer Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are a &#8220;smaller reporting company&#8221; under Item 10 of Regulation S-K promulgated under the Exchange Act, and the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following is a discussion and analysis of compensation arrangements of our named executive officers (&#8220;Named Executive Officers&#8221;). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We seek to ensure the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives. Our Named Executive Officers for fiscal year 2025 were as follows:   </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Robert Connelly, President, Chief Executive Officer and Director; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Preetam Shah, Ph.D., Chief Strategy and Financial Officer and Treasurer; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth total compensation paid to our Named Executive Officers for the fiscal year ending on <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-42">December&#160;31, 2025</ix:nonNumeric> and 2024.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Name and Principal Position</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Year</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Salary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:112%">&#8194;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">awards</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Bonus</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Non-Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Incentive Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">All other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(3)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Total</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(4)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert Connelly, </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">632,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">906,960</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">348,000</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,887,660</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer, and Director</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">608,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,093,421</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">334,620</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,036,441</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., </span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">350,612</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">796,143</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201,600</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,331</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,377,686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Strategy and Financial Officer and Treasurer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Haqq, M.D., Ph.D.,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">528,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">328,176</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">221,900</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,078,176</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Head of Research and Development and Chief Medical Officer</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">507,807</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205,365</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">213,280</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">926,452</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts shown represent the aggregate grant date fair value of options granted as calculated in accordance with FASB ASC Topic 718. See Note 2 of the financial statements included in the Original 10-K for the assumptions used in calculating this amount. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Non-equity incentive plan compensation includes discretionary bonuses based on pre-established performance criteria. For fiscal year 2025, the bonuses were paid in February 2026. For fiscal year 2024, the bonuses were paid in February&#8239;2025. Please see the descriptions of the bonuses paid to our Named Executive Officers under &#8220;Narrative Disclosure to Summary Compensation Table&#8221; below, including target amounts for the discretionary annual bonuses.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:8.68pt">All other compensation includes COBRA payments and reimbursements of existing health coverage.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Except as otherwise noted, Named Executive Officers received no compensation other than salaries, bonuses, and stock option awards. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Dr. Shah&#8217;s base salary for fiscal year 2025 was $480,000, of which $350,612 was received due to the prorated start date in March 2025.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Dr. Shah commenced employment as Chief Strategy and Financial Officer and Treasurer of the Company on March 24, 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Narrative Disclosure to Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Robert Connelly</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Effective as of the effective time of the Merger, our Board appointed Mr. Connelly as President and Chief Executive Officer of the Company. Prior to the completion of the Merger, Mr. Connelly was Chief Executive Officer of Former Elicio. Former Elicio entered into an employment agreement with Mr. Connelly in November 2018. The agreement provides for a base salary, which may be modified from time to time at the discretion of the Board, and an annual performance bonus awarded at the discretion of the Board. The agreement also provided for an initial option grant and a signing bonus. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Connelly&#8217;s base salary for fiscal year 2024 was $608,400, increased to $632,700 for fiscal year 2025, and, effective as of January 1, 2026, increased to $664,400 for fiscal year 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For 2024, Mr. Connelly&#8217;s target bonus percentage was 55% of his base salary. Mr. Connelly&#8217;s bonus target remained at 55% of his base salary for 2025 and remains at 55% for 2026. In 2025, Mr. Connelly was paid a discretionary cash bonus, based on the achievement of 2024 Company corporate goals, of $334,620, which represented 100% of his target bonus. In 2026, Mr. Connelly was paid a discretionary cash bonus, based on the achievement of 2025 Company corporate goals, of $348,000, which represented 100% of his target bonus. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, we granted Mr.&#8239;Connelly an option to purchase 225,137 shares of our common stock under the 2021 Incentive Award Plan (the "2021 Plan"). Mr.&#8239;Connelly&#8217;s option vests over four years with 25% vesting on the first&#8239;anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Mr.&#8239;Connelly being employed or in continuous service to Elicio as defined in the 2021 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Plan through such vesting date. In September 2024, Mr. Connelly was granted an option to purchase 91,600 shares of our common stock under the 2021 Plan. Mr.&#8239;Connelly&#8217;s option vests over two years with 50% vesting on the first&#8239;anniversary of the grant date and the remainder vesting on the second anniversary of the grant date, subject to Mr.&#8239;Connelly being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In February 2025, we granted Mr. Connelly an option to purchase 121,600 shares of our common stock under the 2021 Plan. Mr. Connelly&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Mr. Connelly being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In February 2026, we granted Mr. Connelly an option to purchase 147,200 shares of our common stock and 73,600 restricted stock units (&#8220;RSUs&#8221;) under the 2021 Plan. Mr. Connelly&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Mr. Connelly being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. Mr. Connelly&#8217;s RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to Mr. Connelly being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Mr.&#8239;Connelly is entitled to certain benefits in connection with a termination of his employment or a change of control as discussed below under &#8220;Potential Payments upon Termination or Change of Control.&#8221;  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Preetam Shah, Ph.D.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company entered into an employment agreement with Dr. Shah on March 21, 2025, effective as of March 24, 2025. The agreement provides for an initial base salary of $480,000, which can be increased from time to time at the discretion of the Board. Dr. Shah is also eligible for an annual performance bonus awarded at the discretion of the Board, with his target bonus equal to 40% of his base salary. The agreement also provided for an initial option grant. Further, pursuant to the terms of the agreement, Dr. Shah received a 15-month reimbursement by the Company, beginning April 1, 2025, for his then-current health coverage premium so long as he continues to pay such health coverage premium, less the premium he would have received if he elected to be initially covered by the Company&#8217;s insurance policies. In the event such health coverage becomes unavailable to Dr. Shah, Dr. Shah will become eligible to participate in the Company&#8217;s benefit plans. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Shah&#8217;s base salary for fiscal year 2025 was $480,000, of which $350,612 was received due to the prorated start date in March 2025. Effective as of January 1, 2026, Dr. Shah&#8217;s base salary increased to $504,000 for fiscal year 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For 2025, Dr. Shah's bonus target was 40% of his base salary. Dr. Shah&#8217;s bonus target remains at 40% of his base salary for 2026. In 2026, Dr. Shah was paid a discretionary cash bonus, based on the achievement of 2025 Company corporate goals, of $201,600, which represented 105% of his target bonus. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the commencement of his employment, the Company granted Dr. Shah an option to purchase 191,624 shares of our common stock, equal to 1.2% of the total shares of the Company&#8217;s common stock outstanding as of April 15, 2025, the grant date of the option. Dr. Shah&#8217;s option vests over four years with 25% vesting on the first anniversary of his start date of employment and the remainder vesting in 36 equal monthly installments thereafter, subject to Dr. Shah being employed or in continuous service to the Company as provided in the Company&#8217;s 2024 Inducement Incentive Award Plan through each such vesting date. In February 2026, we granted Dr. Shah an option to purchase 47,900 shares of our common stock and 24,000 RSUs under the 2021 Plan. Dr. Shah&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Dr. Shah being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. Dr. Shah&#8217;s RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to Dr. Shah being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2025, Dr. Shah received $29,331 in other compensation relating to COBRA payments and reimbursements of existing health coverage. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr.&#8239;Shah is entitled to certain benefits in connection with a termination of his employment or a change of control as discussed below under &#8220;Potential Payments upon Termination or Change of Control.&#8221;  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Chris Haqq, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Effective as of the effective time of the Merger, the Board appointed Dr. Haqq as Executive Vice President, Head of Research and Development and Chief Medical Officer of the Company. Prior to the completion of the Merger, Dr. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Haqq was Executive Vice President, Head of Research and Development and Chief Medical Officer of Former Elicio. Former Elicio entered into an offer letter with Dr. Haqq in September 2019. The agreement provides for a base salary, which may be modified from time to time at the discretion of the Board, and an annual performance bonus awarded at the discretion of the Board. The agreement also provided for an initial grant of restricted stock units, which was granted in October 2019, pursuant to the terms of the offer letter, accelerated and vested in full upon the consummation of the Merger and were settled in Elicio common stock immediately prior to the consummation of the Merger. Additionally, under the terms of his offer letter, Dr. Haqq is also entitled to an annual allowance to be used for the rental or purchase of an apartment near Elicio&#8217;s headquarters previously in Cambridge, Massachusetts and now in Boston, Massachusetts, with such annual allowance subject to applicable taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Haqq&#8217;s base salary for fiscal year 2024 was $507,807, increased to $528,100 for fiscal year 2025, and, effective as of January 1, 2026, increased to $554,600 for fiscal year 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For 2024, Dr. Haqq&#8217;s bonus target was 40% of his base salary. Dr. Haqq&#8217;s bonus target remained at 40% of his base salary for 2025 and remains at 40% for 2026. In 2025, Dr. Haqq was paid a discretionary cash bonus, based on the achievement of 2024 Company corporate goals and individual goals applicable to Dr. Haqq, of $213,280, which represented 105% of his target bonus. In 2026, Dr. Haqq was paid a discretionary cash bonus, based on the achievement of 2025 Company corporate goals, of $221,900, which represented 105% of his target bonus.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, we granted Dr.&#8239;Haqq an option to purchase 28,200 shares of our common stock under the 2021 Plan. Dr.&#8239;Haqq&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Dr.&#8239;Haqq being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In September 2024, we granted Dr. Haqq an option to purchase 28,200 shares of our common stock under the 2021 Plan. Dr. Haqq&#8217;s option vests over two years with 50% vesting on the first&#8239;anniversary of the grant date and the remainder vesting on the second anniversary of the grant date, subject to Dr. Haqq being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In February 2025, we granted Dr. Haqq an option to purchase  44,000 shares of our common stock under the 2021 Plan. Dr. Haqq&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Dr. Haqq being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In February 2026, we granted Dr. Haqq an option to purchase 50,900 shares of our common stock and 25,400 RSUs under the 2021 Plan. Dr. Haqq&#8217;s option vests over four years with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Dr. Haqq being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. Dr. Haqq&#8217;s RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to Dr. Haqq being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr.&#8239;Haqq is entitled to certain benefits in connection with a termination of his employment or a change of control as discussed below under &#8220;Potential Payments upon Termination or Change of Control.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Other Elements of Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Retirement Savings and Health and Welfare Benefits</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Connelly, Dr. Shah, and Dr. Haqq (the &#8220;Named Executive Officers&#8221;) are eligible to participate in our 401(k) program on the same terms as other full-time employees, subject to their continuing employment. We believe that providing a vehicle for tax-deferred retirement savings through a 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our Named Executive Officers, in accordance with our compensation policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All of our full-time employees, including our Named Executive Officers, are eligible to participate in our health and welfare plans, including medical, dental and vision benefits; short-term and long-term disability insurance; and life and Accidental Death and Dismemberment insurance, subject to their continuing employment and the terms of their employment agreement. For 2025, commencing upon his employment, Dr. Shah received reimbursement from the Company for his then current health coverage premium so long as he continued to pay such current health coverage premium, less the premium he would have paid if he had elected to be initially covered by the Company&#8217;s insurance coverage. In the event such health coverage becomes unavailable to Dr. Shah, Dr. Shah will become eligible to participate in the Company&#8217;s benefit plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Perquisites and Other Personal Benefits</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We determine perquisites on a case-by-case basis and will provide a perquisite to a Named Executive Officer when we believe it is necessary to attract or retain the Named Executive Officer. In 2024 and 2025, for Mr. Connelly and Dr. Haqq, we did not provide any perquisites or personal benefits not otherwise made available to our other employees. For 2025, commencing upon his employment, Dr. Shah received reimbursement from the Company for his then current health coverage premium so long as he continued to pay such current health coverage premium, less the premium he would have paid if he had elected to be initially covered by the Company&#8217;s insurance coverage.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Outstanding Equity Awards at 2025 Fiscal Year End</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table lists all outstanding equity awards held by our Named Executive Officers as of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-43">December&#160;31, 2025</ix:nonNumeric>.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Option Awards</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Stock Awards</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Vesting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Commencement</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(#)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unexercisable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(#)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Expiration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">that</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Have</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Not</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(#)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Market</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Units of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">that</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Have</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Not</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert Connelly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/8/2020 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/8/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11/28/2022 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147,912</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11/28/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2024 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">112,568</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">112,569</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">91,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4/15/2025 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">191,624</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4/15/2035</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Haqq, M.D, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3/31/2022 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,244</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">376</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3/31/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11/28/2022 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99,891</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11/28/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option vests as to 25% of the shares on the first anniversary of the vesting commencement date and thereafter 1/36th of the shares subject to the award on each monthly anniversary of the vesting commencement date, subject to the holder&#8217;s continued service to Elicio through each vesting date.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option vests as to 1/36th of the shares subject to the award on each monthly anniversary of the vesting commencement date, subject to the holder&#8217;s continued service to Elicio through each vesting date.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option vested upon the Company submitting an Investigational New Drug Application to the Food and Drug Administration for any of the Company&#8217;s Amphiphile vaccine candidates prior to December 31, 2020.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option vests as to 50% of the shares on the first anniversary of the vesting commencement date and 50% of the shares on the second anniversary of the vesting commencement date, subject to the holder's continued service to Elicio through each vesting date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Potential Payments Upon Termination or Change of Control</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, we entered into an executive severance plan (the &#8220;Severance Plan&#8221;) covering the Named Executive Officers, superseding and replacing the severance benefits they would otherwise be entitled to receive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under our Severance Plan encompassing each of our Named Executive Officers, if such Named Executive Officer&#8217;s employment with us is terminated without Cause (as defined in the Severance Plan), the applicable Named Executive Officer will be entitled to receive an amount equal to the product of (i) the Normal Multiplier (as defined in the Severance Plan) and (ii) the Named Executive Officer&#8217;s then-current base salary. For our Named Executive Officers, the applicable severance is 9 months of continued base salary (or 12 months for Mr.&#8239;Connelly). The Named Executive Officers are also entitled to continue participating in our health benefits for their applicable Severance </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Period (as defined in the Severance Plan). In the case of Mr.&#8239;Connelly, any outstanding unvested, time-based equity awards scheduled to vest during the 12 months following his termination date will fully vest as of the effective date of Mr.&#8239;Connelly&#8217;s termination of employment. In the event of a termination without Cause (as defined in the Severance Plan) or resignation for Good Reason (as defined in the Severance Plan) during the Change in Control Period (as defined in the Severance Plan), the applicable Named Executive Officer will be entitled to receive an amount equal to the product of (i) the CIC Multiplier (as&#8239;defined in the Severance Plan) and (ii) the Named Executive Officer&#8217;s then-current base salary and then-current target annual bonus opportunity, payable as a one-time lump sum. For our Named Executive Officers, the applicable severance is equal to 12 months of base salary (or 18 months for Mr.&#8239;Connelly). The Named Executive Officers are also entitled to continue participating in our health benefits for their applicable CIC Severance Period (as defined in the Severance Plan). Additionally, any outstanding unvested equity awards held by the Named Executive Officer under the Company&#8217;s then-current outstanding equity incentive plan(s) will become fully vested as of the effective date of the Named Executive Officer&#8217;s termination of employment. The foregoing severance benefits are subject to the applicable Named Executive Officer&#8217;s delivery of an executed release of claims against us within 60 days following termination or such shorter time period as may be set forth, and continued compliance with the Named Executive Officer&#8217;s confidentiality obligations or restrictive covenants in effect prior to termination.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the employment agreement entered into between the Company and Dr. Shah, in the event Dr. Shah&#8217;s employment is terminated by the Company without Cause or Dr. Shah resigns for Good Reason (whether or not in connection with a Change in Control (as defined in the Severance Plan)), Dr. Shah will be entitled to an amount equal to the Company&#8217;s contribution of the premium for continuation of coverage under COBRA for the Severance Period in accordance with the Severance Plan, regardless of whether the Company continues to offer such health coverage benefits or whether the Company is required to pay for such health coverage benefits to other employees. In this event, the Company will pay such amount in a single lump sum on such date in accordance with the terms of the Severance Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Policies and Practices Related to the Grant of Certain Equity Awards </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our equity awards, including stock options, are granted in connection with our yearly compensation cycle and regularly scheduled meetings of the Compensation Committee. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Typically, our practice is to make annual award grants in the first quarter of each fiscal year. Our policy is to not grant stock options or similar awards in anticipation of the release of material non-public information and to not time the release of material non-public information based on equity award grant date, but some option grants may be granted close in time to the release of material non-public information to the extent those options are being granted upon the hiring of new executive officers or in connection with annual grants made in connection with our yearly compensation cycle or as part of our director compensation policy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2025, we did not time the disclosure of material non-public information for the purpose of affecting the value of executive compensation, and none of our named executive officers were awarded options with an effective grant date during any period beginning four business days before the filing or furnishing of a Form 10-Q, Form 10-K, or Form 8-K that disclosed material non-public information, and ending one business day after the filing or furnishing of such reports. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Director Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We amended and restated our compensation policy for our non-employee directors (&#8220;Director Compensation Program&#8221;) effective as of December 2023, which has been further amended from time to time. Such Director Compensation Program is subject to further amendment by the Board of Directors as appropriate. Pursuant to the Director Compensation Program, our non-employee directors receive cash compensation as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Each non-employee director will receive an annual cash retainer in the amount of $40,000 per year. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The non-executive chairperson will receive an additional annual cash retainer in the amount of $35,000 per year. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The chairperson of the Audit Committee will receive additional annual cash compensation in the amount of $15,000 per year for such chairperson&#8217;s service on the Audit Committee. Each non-chairperson member of the Audit Committee will receive additional annual cash compensation in the amount of $7,500 per year for such member&#8217;s service on the Audit Committee. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The chairperson of the Compensation Committee will receive additional annual cash compensation in the amount of $12,000 per year for such chairperson&#8217;s service on the Compensation Committee. Each non-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">chairperson member of the Compensation Committee will receive additional annual cash compensation in the amount of $6,000 per year for such member&#8217;s service on the Compensation Committee. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The chairperson of the Nominating and Corporate Governance Committee will receive additional annual cash compensation in the amount of $10,000 per year for such chairperson&#8217;s service on the Nominating and Corporate Governance Committee. Each non-chairperson member of the Nominating and Corporate Governance Committee will receive additional annual cash compensation in the amount of $5,000 per year for such member&#8217;s service on the Nominating and Corporate Governance Committee. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the Director Compensation Program, as amended and restated by the Board of Directors in December 2023 and as further amended from time to time, each non-employee director will automatically be granted an option to purchase 15,800 shares of our common stock upon the director&#8217;s initial appointment or election to our Board of Directors (the &#8220;Initial Grant&#8221;) and an option to purchase 7,900 shares of our common stock automatically on the date of each annual stockholder&#8217;s meeting thereafter (the &#8220;Annual Grant&#8221;), unless otherwise approved by the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Initial Grant will vest as to 1/36th of the underlying shares on a monthly basis over three years, subject to continued service through each applicable vesting date. The Annual Grant will vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder&#8217;s meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. The exercise price per share of director options is equal to the fair market value of a share of our common stock on the grant date, and the director options will vest in full upon (i) a termination of service due to the director&#8217;s death or Disability (as defined in the 2021 Plan) or (ii) the consummation of a Change in Control (as defined in the 2021 Plan).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Each non-employee director is entitled to reimbursement from the Company for all reasonable, documented, out-of-pocket and other business expenses incurred by the non-employee director in the performance of his or her duties to the Company in accordance with the Company&#8217;s applicable expense reimbursement policies and procedures as in effect from time to time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth information concerning the compensation earned by our non-employee directors during the year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-44">December&#160;31, 2025</ix:nonNumeric>.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">or Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">in Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Julian Adams, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">120,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carol Ashe</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Allen Nissenson, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">90,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Yekaterina (Katie) Chudnovsky</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert R. Ruffolo, Jr., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Karen Wilson</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jay Venkatesan, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">77,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts shown represent the aggregate grant date fair value of options granted during fiscal year 2025 as calculated in accordance with FASB ASC Topic 718. See Note 2 of the financial statements included in the Original 10-K for the assumptions used in calculating this amount.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Non-employee directors only received cash fees and stock option awards as compensation for their service on the Board of Directors.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-45">December&#160;31, 2025</ix:nonNumeric>, Dr. Adams held options to purchase 67,416 shares of our common stock, of which options to purchase 59,460 shares were vested.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-46">December&#160;31, 2025</ix:nonNumeric>, Ms. Ashe held options to purchase 31,009 shares of our common stock, of which options to purchase 23,053 shares were vested.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-47">December&#160;31, 2025</ix:nonNumeric>, Dr. Nissenson held options to purchase 22,989 shares of our common stock, of which options to purchase 15,089 shares were vested.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-48">December&#160;31, 2025</ix:nonNumeric>, Ms. Chudnovsky held options to purchase 20,625 shares of our common stock, of which options to purchase 12,725 shares were vested.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-49">December&#160;31, 2025</ix:nonNumeric>, Dr. Ruffolo held options to purchase 33,178 shares of our common stock, of which options to purchase 25,222 shares were vested.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-50">December&#160;31, 2025</ix:nonNumeric>, Ms. Wilson held options to purchase 22,989 shares of our common stock, of which options to purchase 15,089 shares were vested.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-51">December&#160;31, 2025</ix:nonNumeric>, Dr. Venkatesan held options to purchase 215,878 shares of our common stock, of which options to purchase 207,978 shares were vested.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_129"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth certain information regarding the ownership of Elicio&#8217;s common stock as of April&#160;9, 2026 by: (i) each director and nominee for director; (ii) each of the executive officers named in the Summary Compensation Table; (iii) all executive officers and directors of Elicio as a group; and (iv) all those known by Elicio to be beneficial owners of more than five percent of its common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Percentage of ownership is based on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-52">18,704,798</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> shares of common stock outstanding on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">April&#160;9, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Beneficial Owner(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Percent of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5% and Greater Stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">GKCC, LLC</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,552,139</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33.0</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Named Executive Officers and Directors:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Yekaterina (Katie) Chudnovsky</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,772,764</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42.4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Julian Adams, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67,416</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carol Ashe</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,009</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert Connelly</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">439,694</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Karen J. Wilson</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,860</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Robert Ruffolo, Jr., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,178</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Allen R. Nissenson, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,989</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Haqq, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,708</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pete DeMuth, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">137,724</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jay Venkatesan, M.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">436,101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,890</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">All current executive officers and directors as a group (11 persons)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,202,333</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46.2</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Less than one percent.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, Elicio believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-53">18,704,798</ix:nonFraction> shares outstanding on April&#160;9, 2026, adjusted as required by the rules promulgated by the SEC. Unless otherwise noted below, the address for persons listed in the table is c/o Elicio Therapeutics, Inc. 451 D Street, Boston, Massachusetts 02210.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes (i) 5,416,212 shares of our common stock held directly by GKCC, LLC, (ii) 1,032,702 shares of common stock underlying pre-funded warrants and, (iii) 103,225 shares of common stock underlying common warrants exercisable within 60 days of April&#160;9, 2026. Yekaterina (Katie) Chudnovsky has sole voting and investment control over the shares held by GKCC, LLC and may be deemed to beneficially own such shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 20,625 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026, (ii) 5,416,212 shares of common stock held by GKCC, LLC of which Yekaterina (Katie) Chudnovsky has sole voting and investment control over and may be deemed to beneficially own such shares, (iii) 1,032,702 shares of common stock underlying pre-funded warrants exercisable within 60 days of April&#160;9, 2026 held by GKCC, LLC of which Yekaterina (Katie) Chudnovsky has sole voting and investment control over and may be deemed to beneficially own such shares, (iv) 1,600,000 shares of common stock underlying pre-funded warrants exercisable within 60 days of April&#160;9, 2026,  (v) 103,225 shares of common stock underlying common warrants exercisable within 60 days of April&#160;9, 2026 held by GKCC, LLC of which Yekaterina (Katie) Chudnovsky has sole voting and investment control over and may be deemed to beneficially own such shares, and (vi) 1,600,000 shares of common stock underlying common warrants exercisable within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 67,416 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 31,009 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 46,970 shares of our common stock held directly by Robert Connelly and (ii) 392,724 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 1,871 shares of our common stock held directly by Karen J. Wilson and (ii) 22,989 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 33,178 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 22,989 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 31,981 shares of our common stock held directly by Christopher Haqq, M.D., Ph.D. and (ii) 148,727 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 743 shares of our common stock held directly by Peter DeMuth, Ph.D. and (ii) 136,981 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 169,270 shares of our common stock held directly by Jay R. Venkatesan, M.D., (ii) 953 shares of our common stock held by the Venkatesan Family Trust, (iii) 50,000 shares of common stock underlying common warrants exercisable within 60 days of April&#160;9, 2026, and (iv) 215,878 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of 55,890 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of April&#160;9, 2026.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of the shares described in footnotes 3 through 13 above. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Equity Compensation Plan Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides certain aggregate information with respect to all of Elicio&#8217;s equity compensation plans in effect as of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-54">December&#160;31, 2025</ix:nonNumeric>.    </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(c)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Plan Category</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">be issued upon exercise of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">outstanding options,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">warrants and rights</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">exercise price of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">outstanding options,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">warrants and rights</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">remaining available for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">future issuance under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">equity compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">plans (excluding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">securities reflected in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">column (a))</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,520,047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">460,025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,101,156</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">188,611</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,621,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">648,636</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">These plans consist of the 2021 Plan, the Second Amended and Restated 2015 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The 2021 Plan contains an &#8220;evergreen&#8221; provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year equal to the lesser of (i) 5% of the number of shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year, or (ii) if our Board acts prior to the first day of the fiscal year, such lesser amount that our Board determines for purposes of the annual increase of the fiscal year.  As of January&#160;1, 2026, the 2021 Plan was increased by 5% of shares outstanding as of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-55">December&#160;31, 2025</ix:nonNumeric> pursuant to such evergreen provision. The ESPP also contains an &#8220;evergreen&#8221; provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year equal to the lesser of (i) 1% of the number of shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year, or (ii) if our Board acts prior to the first day of the fiscal year, such lesser amount that our Board determines for purposes of the annual increase of the fiscal year. As of January&#160;1, 2026, the ESPP was increased by 1% of shares outstanding as of <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-56">December&#160;31, 2025</ix:nonNumeric> pursuant to such evergreen provision.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">These plans consist of the Former Elicio 2022 Equity Incentive Plan, as amended, the former Elicio 2012 Equity Incentive Plan, as amended, and the Elicio 2024 Inducement Incentive Award Plan for the issuance of inducement stock options granted pursuant to Nasdaq Rule 5635(c)(4). In connection with the Merger, the Company assumed the Former Elicio 2022 Equity Incentive Plan and the Former Elicio 2012 Equity Incentive Plan (the &#8220;Former Elicio Plans&#8221;) and all stock options issued and outstanding under the Former Elicio Plans. Each outstanding and unexercised option to purchase Former Elicio common stock was adjusted with such Company stock options henceforth representing the right to purchase a number of shares of the Company&#8217;s common stock based on the Merger exchange ratio of 0.0181. Any restriction on the exercise of any Former Elicio stock options assumed by the Company will continue in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such Former Elicio stock options will otherwise remain unchanged; provided, however, that Elicio&#8217;s Board of Directors or a committee thereof will assume the responsibility and the authority of Former Elicio&#8217;s Board of Directors or any committee thereof with respect to each Former Elicio stock option assumed by the Company. See Note 8 of the financial statements included in the Original 10-K for descriptions of each of the equity plans. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_137"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Related Person Transactions Policy and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors has adopted a related party transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related party transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and a related party were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our Audit Committee will consider all relevant facts and circumstances as appropriate, such as if the transaction is on terms comparable to those that could be obtained in arm&#8217;s length dealings with an unrelated third party, the extent of the related party&#8217;s interest in the transaction, as well as taking into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Certain Related Person Transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following is a summary of transactions since January 1, 2024 to which we have been a party, in which the amount involved exceeded or will exceed the lesser of (x) $120,000 or (y) 1% of our total assets at December 31, 2025, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest other than compensation and other arrangements that are described in the section titled &#8220;Executive Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers, principal stockholders, and their affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All of the transactions set forth below were approved by a majority of our Board of Directors or our Audit Committee. We believe we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third parties. It is our intention to ensure that all future transactions between us and our officers, directors and principal stockholders and their affiliates are approved by our Audit Committee, or a majority of the members of our Board of Directors, including a majority of the independent and disinterested members of our Board of Directors, and are on terms no less favorable to us than those that we could obtain from unaffiliated third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">March 2024 Private Placement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, we entered into a subscription agreement (the "March Subscription Agreement") with GKCC, LLC, an entity controlled by Yekaterina (Katie) Chudnovsky, a member of our Board of Directors, and which owns greater than 20% of our shares of common stock outstanding (the &#8220;Purchaser&#8221;), providing for the issuance and sale by us to the Purchaser of pre-funded warrants to purchase up to 1,032,702 shares of our common stock, par value $0.01 per share (the "March Pre-Funded Warrants"), at a purchase price per March Pre-Funded Warrant of $5.81 (the "March Offering"). The March Offering closed on March 19, 2024 (the &#8220;March Offering Closing Date&#8221;). Each March Pre-Funded Warrant is exercisable at any time on or after the March Offering Closing Date at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the March Pre-Funded Warrant. The gross proceeds to us from the March Offering were approximately $6.0 million. In connection with the March Offering, we granted the Purchaser certain customary registration rights with respect to the shares of our common stock issuable upon exercise of the March Pre-Funded Warrants and, on June 3, 2024 filed a registration statement on Form S-3 with respect to such shares, which registration statement became effective on June 11, 2024. The March Subscription Agreement contains customary terms and conditions for a transaction of this type, including certain customary indemnification rights and certain customary cash penalties on us for our failure to satisfy specified filing and effectiveness time periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">July 2024 Public Offering</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In July 2024, we closed an underwritten public offering (the &#8220;July Offering&#8221;) consisting of shares of our common stock, pre-funded warrants (the &#8220;July Pre-Funded Warrants&#8221;) and common stock purchase warrants (the &#8220;July Common Warrants&#8221;), as further described below, in which Yekaterina (Katie) Chudnovsky, a member of our Board of Directors and holder of more than 20% of our common stock outstanding, and Jay Venkatesan, a member of our Board of Directors, along with trusts affiliated with Jay Venkatesan, participated. Ms. Chudnovsky purchased 1,600,000 July Pre-Funded Warrants and accompanying July Common Warrants for an aggregate purchase price of $7,984,000 and Mr. Venkatesan and his affiliated trusts purchased 200,000 July Pre-funded Warrants and accompanying July Common Warrants for an aggregate purchase price of $998,000, with such July Pre-Funded Warrants and July Common Warrants subject to the terms and conditions of such securities detailed below.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The July Offering consisted of (i) 500,000 shares of our common stock, par value $0.01 per share (the &#8220;July Shares&#8221;) and (ii) 1,800,000 July Pre-Funded Warrants, together with the July Common Warrants to purchase up to 2,300,000 shares of our common stock. Each July Share and accompanying July Common Warrant were sold together at a combined offering price of $5.00 per July Share and accompanying July Common Warrant, and each July Pre-Funded Warrant and accompanying July Common Warrant were sold together at a combined offering price of $4.99 per July Pre-Funded Warrant and accompanying July Common Warrant, which represented the combined purchase price per July Pre-Funded Warrant and accompanying July Common Warrant less the $0.01 per share exercise price for each such July Pre-Funded Warrant. The July Common Warrants have an exercise price of $5.00 per share, were immediately exercisable and will expire five years from the issuance date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Senior Secured Convertible Note Financing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In August 2024, we entered into a securities purchase agreement (the "August Securities Purchase Agreement") pursuant to which we issued a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 (the "Convertible Note") in the principal amount of $20.0 million (the "Note Financing") to the Purchaser. Pursuant to the terms of the Convertible Note, the Convertible Note would mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note was to accrue and be payable quarterly in cash on the principal amount equal to 3% per annum, with the initial interest payment date to be June 30, 2025. The Convertible Note was secured by a (i) first priority lien on substantially all assets of the Company and our subsidiaries, pursuant to a security agreement and (ii) first priority lien on intellectual property of the Company, pursuant to an intellectual property security agreement. The Convertible Note was convertible into shares of Elicio common stock, in whole or in part, at the option of the Purchaser at any time, based on a Conversion Price of $5.81 per share of common stock, subject to adjustments and satisfaction of certain conversion conditions. The Convertible Note contained customary terms and covenants and customary events of default. We granted the Purchaser certain customary registration rights with respect to the shares of common stock issuable upon conversion of the Convertible Note, and on November 13, 2024, filed a registration statement on Form S-3 with respect to such shares, which registration statement became effective on November 20, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If at any time from and after the date of the August Securities Purchase Agreement and for so long as certain conversion conditions are satisfied, the closing price of the common stock on Nasdaq equals or exceeds 135% of the Conversion Price for 20 trading days in a 30 trading day period, then we had the right to require the Purchaser to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of common stock, as further described in the Convertible Note. In March 2025, we exercised our right under the Convertible Note to require the Purchaser to convert the full amount of the Convertible Note, including all accrued and unpaid interest into shares of our common stock. We issued 3,500,573 shares of common stock to the Purchaser in exchange for the principal balance of $20.0 million plus $0.3 million in accrued interest, in satisfaction in full of the Convertible Note.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Personal Gift</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In April 2025, Ms. Chudnovsky, a member of our Board of Directors and a holder of greater than 20% of our common stock outstanding made a gift to us in the amount of $640,757 to be used for purposes of the continued development and manufacturing of our product candidates. The Company returned the amount in full to Ms. Chudnovsky in April 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Senior Secured Promissory Note Financing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In June 2025, the Company entered into a note purchase agreement (the &#8220;June 2025 Promissory Note Financing&#8221;) with the Purchaser pursuant to which the Company issued a Senior Secured Promissory Note (the &#8220;June 2025 Promissory Note&#8221;) in the principal amount of $10.0&#160;million. The June 2025 Promissory Note will mature on June 3, 2028, or such earlier date as the June 2025 Promissory Note is required or permitted to be repaid in accordance with the terms of the June 2025 Promissory Note and is a senior, secured obligation of the Company and its subsidiaries. Interest will accrue and be payable in cash on the principal amount at the rate of the sum of the Prime Rate (as defined in the June 2025 Promissory Note) plus 5.00%, provided that the maximum interest rate shall not exceed 12.5% per annum, with an initial interest payment date of July 1, 2026. As of December&#160;31, 2025, the interest rate was 12.5% per annum. The first 24 months of the June 2025 Promissory Note is an interest only period, with payments towards the principal commencing on July 1, 2027 as shown in the below future principal payments table. The Company may prepay the June 2025 Promissory Note in full at any time, but the payment must include the principal, all accrued unpaid interest, and a prepayment fee in one aggregate payment. If the prepayment occurs during the first, second, or third year of the June 2025 Promissory Note, the prepayment fee will be equal to the outstanding principal balance prepaid multiplied by 3%, 2%, or 1%, respectively. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in connection with the June 2025 Promissory Note Financing, the Company issued to the Purchaser the June 2025 Warrant to purchase an aggregate of 103,225 shares of the Company&#8217;s common stock. The June 2025 Warrant has an exercise price of $7.75 per share, is immediately exercisable and expires five years from the date of issuance. The Purchaser will not have the right to exercise any portion of the June 2025 Warrant if the Purchaser (together with its affiliates) would beneficially own in excess of 49.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the June 2025 Warrant. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Director Independence </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors currently consists of eight members. Our Board of Directors has determined all of our directors, other than Dr. Venkatesan, Ms. Chudnovsky and Mr. Connelly, qualify as &#8220;independent&#8221; directors in accordance with the Nasdaq listing requirements. Dr. Venkatesan is not considered independent because he was an employee of Angion for a period of time within the prior three years. Mr. Connelly is not considered independent as he is currently an employee of Elicio. Ms. Chudnovsky is not considered independent because of her significant ownership of Elicio&#8217;s securities. In addition, as required by the Nasdaq rules, our Board of Directors has made a subjective determination as to each independent director that no relationships exist that, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Indemnification Agreement with Directors and Officers</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We provide indemnification for our directors and executive officers so that they will be free from undue concern about personal liability in connection with their service to Elicio. Under our Amended and Restated Bylaws, we are required to indemnify our directors and executive officers to the extent not prohibited under Delaware or other applicable law. We have also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that we will indemnify the officer or director, under the circumstances and to the extent provided for in the agreement, for expenses, losses and liabilities (including all interest, taxes, assessments and other charges in connection therewith) that he or she may incur in connection with any proceeding or in any way connected with, resulting from or relating to his or her status as a director or officer of the Company or any of our subsidiaries, and otherwise to the fullest extent permitted under Delaware law and our Amended and Restated Bylaws.</span></div><div id="i669fa5055ce74f1cb474bfb525237968_145"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 14. Principal Accountant Fees and Services.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-57">Baker Tilly US, LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-58">Tewksbury, MA</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-59">23</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth all fees billed for professional audit, tax and other services rendered by Baker Tilly US, LLP</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Audit Fees</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">572,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">567,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Audit-Related Fees</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Tax Fees</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Fees</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">572,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">567,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Baker Tilly US, LLP served as Elicio&#8217;s auditor for the years ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-60">December&#160;31, 2025</ix:nonNumeric> and 2024. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Audit fees are for professional services for the audit of our financial statements, the review of quarterly interim financial statements, and for services that are normally provided by the accountant in connection with other regulatory filings or engagements. Fees for the years ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-61">December&#160;31, 2025</ix:nonNumeric> and 2024 include services associated with registration statements and comfort letters, in addition to the 2025 and 2024 audits. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Audit-related fees consist of fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under &#8220;Audit Fees.&#8221; These services include consultations concerning financial accounting and reporting standards.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Tax fees are for compliance and consultation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">All other fees consist principally of all other permissible work performed by Baker Tilly US, LLP that does not meet the above category descriptions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Pre-Approval Policies and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by Elicio&#8217;s independent registered public accounting firm, Baker Tilly US, LLP. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee&#8217;s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee&#8217;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. The Audit Committee has determined that services may be pre-approved by its Chairperson, Karen Wilson. All of the services described above for fiscal years 2025 and 2024 were pre-approved, to the extent applicable, by the Audit Committee or the Audit Committee Chairperson.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee has determined the rendering of services other than audit services by Baker Tilly US, LLP is compatible with maintaining the principal accountant&#8217;s independence.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_153"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">PART IV</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_162"></div><div style="-sec-extract:summary;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 15. Exhibits and Financial Statement Schedules.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Item 15(a). The documents listed below are filed as part of this Amendment No. 1 to Annual Report on Form 10-K/A. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Item 15(a)(1) and (2).        See Item 8 of the Original 10-K. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Item 15(a)(3).      Exhibits: The exhibits listed below are filed with, or incorporated by reference in, this Amendment. </span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Description</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Incorporated by<br/>Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Filed Herewith</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_ex2-1.htm">Agreement and Plan of Merger and Reorganization, dated January 17, 2023, by and among Angion Biomedica Corp., Arkham Merger Sub, Inc. and Elicio Therapeutics, Inc</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/17/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-1.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-3.htm">Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated June 1, 2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-4.htm">Certificate of Amendment (Officer Exculpation) to the Amended and Restated Certificate, dated June 1, 2023.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex3-5.htm">Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation, dated June 1, 2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-2.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/9/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Reference is made to exhibits 3.1 through 3.5.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-4_2.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_3.htm">Form of Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_6.htm">Amended and Restated Registration Rights Agreement, dated as of March 31, 2020, by and among Angion Biomedica Corp. and the investors party thereto.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angion-descriptionofsecuri.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/30/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000119312525016455/d914999dex41.htm">Form of Common Warrant</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/30/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex4-1.htm">Form of Senior Secured Convertible Promissory Note due February 15, 2026.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124031811/ny20031755x4_ex4-1.htm">Form of Common Warrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124031811/ny20031755x4_ex4-2.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/28/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000015/angn-20240318.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/18/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a41elicio-gkccpromissory.htm">Form of Senior Secured Promissory Note due June 3, 2028</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">4.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a42eltxformofwarrantmay2.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a42eltxformofwarrantmay2.htm">orm of Warrant</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-34.htm">Lease Between Elicio Therapeutics, Inc. and RREF II 451D, LLC dated July 21, 2021.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000119312525016455/d914999dex101.htm">Form of Securities Purchase Agreement, dated as of January 29, 2025, by and among Elicio Therapeutics, Inc. and the purchasers party thereto</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/30/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-1.htm">Securities Purchase Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-2.htm">Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-3.htm">IP Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036124036848/ef20033947_ex10-4.htm">Subsidiary Guarantee, dated August 12, 2024, among Elicio Operating Company, Inc., Elicio Securities Corp. and GKCC, LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a102elicio-gkccsecuritya.htm">Security Agreement, dated June 3, 2025, by and between the Company and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a103elicio-gkccipsecurit.htm">IP Security Agreement, dated June 3, 2025, by and between the Company and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a104elicio-gkccsubsidiar.htm">Subsidiary Guarantee, dated June 3, 2025, among Elicio Operating Company, Inc., Elicio Securities Corp. and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000015/angn-20240318.htm">Subscription Agreement, dated as of March 18, 2024, by and between Elicio Therapeutics, Inc. and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/18/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/eltxatm-salesagreement.htm">At Market Issuance Sales Agreement, dated as of March 16, 2026, by and between Elicio Therapeutics, Inc. and B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/eltxatm-salesagreement.htm"> Thalmann &amp;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/eltxatm-salesagreement.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/eltxatm-salesagreement.htm">Co. Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/16/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148524000045/angn-20240630.htm">Capital on DemandTM Sales Agreement, dated as of June 3, 2024, by and between Elicio Therapeutics, Inc. and JonesTrading Institutional Services LLC</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/3/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">1.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex10-8.htm">Form of Indemnification Agreement between Elicio Therapeutics, Inc. and each of its directors and officers.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_ex10-13.htm">Information Rights Letter, dated May 30, 2023, by and between Clal Biotechnology Industries Ltd. and Elicio Therapeutics, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/2/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.15#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-29.htm">Employment Agreement between Elicio Therapeutics, Inc. and Robert Connelly, dated as of November 15, 2018.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.29+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.16#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-30.htm">Offer Letter between Elicio Therapeutics, Inc. and Dr. Christopher Haqq, dated as of September 29, 2019.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.30+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.17#</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-32.htm">Employment Letter, by and between Elicio Therapeutics, Inc. and Peter DeMuth, dated as of April 13, 2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.32+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.18#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/confidential-elicioemplo.htm">Employment Agreement, dated March 21, 2025, by and between Elicio Therapeutics, Inc. and Preetam Shah.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/24/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148523000086/eltxpipesubscriptionagmt.htm">Subscription Agreement, dated as of December 22, 2023, by and between the Company and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">12/22/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.20#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-27.htm">Elicio Therapeutics, Inc. 2012 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.27+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.21#</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-28.htm">Elicio Therapeutics, Inc. 2022 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.28+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.22&#8224;</span></div><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123014578/ny20006674x9_ex10-25.htm">Exclusive Patent License Agreement, dated January 22, 2016, by and between Elicio Therapeutics, Inc. and the Massachusetts Institute of Technology, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-4/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.25+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_ex10-1.htm">Note Purchase Agreement, dated January 17, 2023, by and between Elicio Therapeutics and Angion Biomedica Corp., and Form of Promissory Note.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/17/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a101elicio-gkccnotepurch.htm">Note Purchase Agreement, dated June 3, 2025, by and between the Company and GKCC, LLC.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">6/4/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.25#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio-arnonxemployeedir.htm">Amended and Restated Non-Employee Director Compensation Policy.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.26#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-executiveseveranc.htm">Executive Severance Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/2/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.27#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5a.htm">Second Amended and Restated 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.5(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.28#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5b.htm">Form of Incentive Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.5(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.29#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5c.htm">Form of Non-Qualified Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.5(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.30#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5d.htm">Form of Stock Option Exercise under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">1/15/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.5(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.31#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6a.htm">2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.6(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.32#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.6(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.33#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6c.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.6(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.34#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6d.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">2/1/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.6(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.35#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio2021employeestockp.htm">2021 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.36#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-inducementincenti.htm">Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.37#</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-formofoptionagree.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Inducement Incentive Award Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.38#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/elicio-formofinducements.htm">Form of Inducement Stock Option Grant Notice and Agreement.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/29/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">19.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio-insidertradingcom.htm">2021 Insider Trading Compliance Policy, as amended</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">19.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">21.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/exhibit2112024.htm">Subsidiaries of the registrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">21.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">23.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio-btconsent202510xk.htm">Consent of independent registered public accounting firm.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">23.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">24.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/eltx-powerofattorney2025.htm">Power of Attorney (reference is made to the signature page hereto).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">24.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-ex311to10xk_aapri.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="elicio-ex312to10xk_aapri.htm">Certification of Principal Financial Officer and Principal Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">32.1&#x5E;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio-exhibit321202510x.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">32.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">32.2&#x5E;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/elicio-exhibit322202510x.htm">Certification of Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/12/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">32.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">97.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/elicio_clawbackpolicynas.htm">Elicio Therapeutics, Inc. Clawback Policy (effective October 31, 2023).</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">3/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">97.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Instance Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Cover Page Interactive Data File</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">#</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">Indicates management contract or compensatory plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">&#x5E;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">       </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">The certification that accompanies the Amendment No. 1 to Annual Report on Form 10-K/A pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_171"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 16. Form 10-K Summary.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">Table of C</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i669fa5055ce74f1cb474bfb525237968_87">ontents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">None.  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i669fa5055ce74f1cb474bfb525237968_179"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURES</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Amendment No. 1 to Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:180pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Elicio Therapeutics, Inc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Date: April&#160;29, 2026&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">/s/ Robert Connelly                                                             </span></div><div style="padding-left:180pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Robert Connelly </span></div><div style="padding-left:180pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">President and Chief Executive Officer</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>elicio-ex311to10xk_aapri.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-ex311to10xk_aapri</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-ex311to10xk_aapri001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-ex311to10xk_aapri001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Exhibit 31.1     CERTIFICATION PURSUANT TO  SECTION 302 OF  THE SARBANES-OXLEY ACT OF 2002     I, Robert Connelly, certify that:     1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Elicio Therapeutics, Inc.; and     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a  material fact necessary to make the statements made, in light of the circumstances under which such statements were  made, not misleading with respect to the period covered by this report.    Date: April 29, 2026    /s/ Robert Connelly    Robert Connelly  President and Chief Executive Officer  (Principal Executive Officer)  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>elicio-ex312to10xk_aapri.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>elicio-ex312to10xk_aapri</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- elicio-ex312to10xk_aapri001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="elicio-ex312to10xk_aapri001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Exhibit 31.2     CERTIFICATION PURSUANT TO  SECTION 302 OF  THE SARBANES-OXLEY ACT OF 2002     I, Preetam Shah, Ph.D., certify that:     1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Elicio Therapeutics, Inc.; and     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a  material fact necessary to make the statements made, in light of the circumstances under which such statements were  made, not misleading with respect to the period covered by this report.    Date: April 29, 2026    /s/ Preetam Shah, Ph.D.    Preetam Shah, Ph.D.  Chief Strategy and Financial Officer  (Principal Financial Officer and  Principal Accounting Officer)  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>angn-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c4d80-2d30-72d4-8279-b11bd397a539,g:0cdb7a4b-5dfb-40da-9c45-c4c5792b6fa8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:angn="http://www.angn.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.angn.com/20251231">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.angn.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.angn.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="angn_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>angn-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c4d80-2d30-72d4-8279-b11bd397a539,g:0cdb7a4b-5dfb-40da-9c45-c4c5792b6fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityShellCompany_019c4dda-90df-7005-89f2-64203ea06cd1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019c4dca-233b-7307-9c73-a6669db6a19c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019c4d97-03e3-778b-bbd1-bbb0132203b5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_019c4dd8-4e9e-7113-b918-343880b87973_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_019c4deb-a2cd-7d90-a99c-99450a467efc_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_019c4ddb-6103-78c7-b826-b93abee76773_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_019c4dd9-07e9-7b64-888a-13b831a4eb2d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_019c4dec-d806-7e92-8459-a525d128c141_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019c4dfc-2e81-7b76-bde0-ae95a1828650_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019c4dcb-0f54-7f86-bb53-c7e146efdc16_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AuditorInformationAbstract_label_en-US" xlink:label="lab_angn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_angn_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_angn_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditorInformationAbstract" xlink:href="angn-20251231.xsd#angn_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AuditorInformationAbstract" xlink:to="lab_angn_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019c4de6-87ff-7725-963c-d9f3da46fccf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019c4db8-a9aa-73b7-9da8-abb05cef9748_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019c4d8f-3d95-777c-bada-5df8bf8cd78a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019c4dca-a1a4-7ff9-a965-a178a329d751_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019c4db5-61dc-7abc-a313-7bb94a5f4f5d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_019c4dd9-d1ad-7fe3-888d-9c037b51fedc_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_019c4ded-3075-7d37-a0dd-6574811368b3_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019c4d9d-bd06-7301-87af-0d30ca50700e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019c4d8e-9805-7f13-b228-4afcb23960b2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019c4d9c-96a5-734e-bc14-3fbcb1c81a30_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019c4d96-6103-75ef-8a1e-33dd2a00aec9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019c4dfd-a503-73bf-b39b-cefe4addf0b0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_019c4db7-4780-710b-b05b-344df891677c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019c4d8d-dc77-70a2-b2e5-9a6427a70218_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019c4dfc-e86b-786c-8e3f-22e2ed931641_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019c4dfb-3b53-78ef-a965-298a29e015d9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019c4d94-eaec-7ada-bbc5-544392b235ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_019c4dc3-1e00-76e6-bc0e-751561a22de4_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_019c4db6-8ea3-71b3-bb8c-44fe7a6d5730_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentDescription_019dd9cc-ebcb-7ba8-91fc-610846a7f944_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019c4d8f-c6a2-7405-ac5d-8b8429f938f6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019c4db4-a575-7cbe-84a4-49017ea6e6c1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019c4dfd-6b10-7991-9495-a83a6fea1209_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019c4d93-83a9-766f-a054-8ff41ec550d9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019c4db3-0db8-7725-8e14-ba7ee8dd7817_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019c4d97-a86e-7b71-bdea-a7848939ad78_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019c4d9d-3ada-7900-9342-ec700b67f312_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019c4d87-b0b9-7341-a556-6ce1e07d79c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019c4db7-f5e8-7a45-937f-6ab3f15c57ce_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>angn-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c4d80-2d30-72d4-8279-b11bd397a539,g:0cdb7a4b-5dfb-40da-9c45-c4c5792b6fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angn.com/role/Cover" xlink:type="simple" xlink:href="angn-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019c4d87-b0b9-76b4-8da3-20c02f8fed90" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentType_019c4d87-b0b9-76b4-8da3-20c02f8fed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_019c4dc3-1e00-719d-b87a-6950b1a7f9cd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentAnnualReport_019c4dc3-1e00-719d-b87a-6950b1a7f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019c4d8d-dc77-7dec-908a-95c03752ab12" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentPeriodEndDate_019c4d8d-dc77-7dec-908a-95c03752ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019c4d8e-9805-7d27-ad6a-bdae69004a7b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentTransitionReport_019c4d8e-9805-7d27-ad6a-bdae69004a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019c4d8f-3d95-7d78-b09b-fbc0b29b1f47" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityFileNumber_019c4d8f-3d95-7d78-b09b-fbc0b29b1f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019c4d8f-c6a2-7720-a236-0a03e3f599b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityRegistrantName_019c4d8f-c6a2-7720-a236-0a03e3f599b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019c4d93-83a9-7c54-9b13-066e06960dc1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019c4d93-83a9-7c54-9b13-066e06960dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019c4d94-eaec-75ba-8875-ff1d7de41cdf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityTaxIdentificationNumber_019c4d94-eaec-75ba-8875-ff1d7de41cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019c4d9c-96a5-74dd-9692-574dc8728ff3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityAddressAddressLine1_019c4d9c-96a5-74dd-9692-574dc8728ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019c4d9d-3ada-7001-8bca-c5c1faf415cc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityAddressCityOrTown_019c4d9d-3ada-7001-8bca-c5c1faf415cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019c4d9d-bd06-7b50-ae18-bc4f01de7da4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityAddressStateOrProvince_019c4d9d-bd06-7b50-ae18-bc4f01de7da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019c4d97-a86e-7f03-b2b9-dd3804494956" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityAddressPostalZipCode_019c4d97-a86e-7f03-b2b9-dd3804494956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019c4d96-6103-7ce7-895f-77f4c99c459c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_CityAreaCode_019c4d96-6103-7ce7-895f-77f4c99c459c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019c4d97-03e3-76e9-b5f6-bcddcf52f443" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_LocalPhoneNumber_019c4d97-03e3-76e9-b5f6-bcddcf52f443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019c4dc4-0d00-73bc-ac93-bd725e9e9583" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_Security12bTitle_019c4dc4-0d00-73bc-ac93-bd725e9e9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019c4dc7-fdf2-7a6e-b8b7-69e6223964bc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_TradingSymbol_019c4dc7-fdf2-7a6e-b8b7-69e6223964bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019c4db5-61dc-7eca-8b6c-3378df467eba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_SecurityExchangeName_019c4db5-61dc-7eca-8b6c-3378df467eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_019c4db6-8ea3-700f-9eab-ed48e1d585cd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_019c4db6-8ea3-700f-9eab-ed48e1d585cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_019c4db7-4780-7fa3-a393-b3a53cf63e46" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityVoluntaryFilers_019c4db7-4780-7fa3-a393-b3a53cf63e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019c4dc9-0ca2-7dfc-b41e-102822990d8f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityCurrentReportingStatus_019c4dc9-0ca2-7dfc-b41e-102822990d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019c4dc9-89b5-7911-9b4a-f4ecaa14ab27" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityInteractiveDataCurrent_019c4dc9-89b5-7911-9b4a-f4ecaa14ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019c4dca-233b-7059-8433-6d7635de9b4d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityFilerCategory_019c4dca-233b-7059-8433-6d7635de9b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019c4dca-a1a4-7630-ad8f-bb7cec69245b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntitySmallBusiness_019c4dca-a1a4-7630-ad8f-bb7cec69245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019c4dcb-0f54-7a9a-99a8-946e2da4c15e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityEmergingGrowthCompany_019c4dcb-0f54-7a9a-99a8-946e2da4c15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019c4dd8-4e9e-73c0-ab72-92403cfd9288" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityExTransitionPeriod_019c4dd8-4e9e-73c0-ab72-92403cfd9288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_019c4dd9-07e9-77fd-a17a-1c5e54cfd798" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_019c4dd9-07e9-77fd-a17a-1c5e54cfd798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_019c4dd9-d1ad-7568-b684-48a5b049f808" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_019c4dd9-d1ad-7568-b684-48a5b049f808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019c4dda-90df-7df1-a6aa-deb2308c15cd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityShellCompany_019c4dda-90df-7df1-a6aa-deb2308c15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_019c4de5-3202-7246-8b3c-441da2d256e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityPublicFloat_019c4de5-3202-7246-8b3c-441da2d256e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019c4de6-87ff-7b96-9841-88eb9fb46f55" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019c4de6-87ff-7b96-9841-88eb9fb46f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019c4dfb-3b53-77bf-8595-89b96805c6e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_EntityCentralIndexKey_019c4dfb-3b53-77bf-8595-89b96805c6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019c4dfc-2e81-722b-8297-8c45c3ba27a8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_AmendmentFlag_019c4dfc-2e81-722b-8297-8c45c3ba27a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019c4dfc-e86b-7179-9f7f-c6510dac969e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_CurrentFiscalYearEndDate_019c4dfc-e86b-7179-9f7f-c6510dac969e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019c4dfd-6b10-7340-9098-ad326c90c1e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentFiscalYearFocus_019c4dfd-6b10-7340-9098-ad326c90c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019c4dfd-a503-7a83-90fc-d4337bf7bb27" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019c4dfd-a503-7a83-90fc-d4337bf7bb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription_019dd9cc-ebcb-73b4-9241-e6eff121cb73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c4d87-b0b9-75e1-89ce-02a41fb61f3f" xlink:to="loc_dei_AmendmentDescription_019dd9cc-ebcb-73b4-9241-e6eff121cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/AuditInformation" xlink:type="simple" xlink:href="angn-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditorInformationAbstract_019dd99e-081a-7a1b-ab21-a37e26760d79" xlink:href="angn-20251231.xsd#angn_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_019dd99e-081a-746b-b83d-611f7aa9c51a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditorInformationAbstract_019dd99e-081a-7a1b-ab21-a37e26760d79" xlink:to="loc_dei_AuditorName_019dd99e-081a-746b-b83d-611f7aa9c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_019dd99e-6346-79c5-8fd6-a6a57c1cc880" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditorInformationAbstract_019dd99e-081a-7a1b-ab21-a37e26760d79" xlink:to="loc_dei_AuditorLocation_019dd99e-6346-79c5-8fd6-a6a57c1cc880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_019dd99e-c8dc-7c2e-857f-220af0592d9e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditorInformationAbstract_019dd99e-081a-7a1b-ab21-a37e26760d79" xlink:to="loc_dei_AuditorFirmId_019dd99e-c8dc-7c2e-857f-220af0592d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>elicio-ex311to10xk_aapri001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elicio-ex311to10xk_aapri001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB<'JK89>,;AZ_,>:Z71M1O-02Z^VV"6CP3>6GES^<DRE%8.K;1P=V.G8UIT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%'2
MDW+_ 'A^= "T4FY?4?G1N7U'YT +12;E_O#\Z6@ HIHD0LRAU++U /(IW2@
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MIMGXM\4:DK6-IK>KQ36D=P-C&,3E@Y4\C(?\E)Z5[,S*@R[!1ZDXI<C&<\4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"%ED=/NF1P<'KDX5<]^^;UMH.Q=2^V2PWKWTC2%I;<?*"H7;C/*@ #UZ\\T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -!KI9XC-!)$)'C+J1O3&1],@C]*I:%H\'A_1+72K:6:6WM8Q'$9B"P4=!D
M9H Y"]\2W^A^(O&=_=W"3Z?I5C;2QVHB()W"4@!MW!+8R2#GCIBM@:YJ>G^)
M]'TO4?LL\.K0RF.2WC9#%+&H<@Y8Y4J3@\$$>_%NZ\)Z;>ZIJ%[<&=TU&U6U
MN[8N/*E50P!(QG(#L.#COC(!I^G>&K>PGLYI+N[O9+*%H+5KIE)B0X!QM49)
M"J,G)P.O)R /\2ZB^G:,Y@+BZN&%O;^7&9&#MQN"J"3M&YR .BFN7^'EPNF7
M>L^$5:X"6,OVG3S=1.CM;2DD<. QVOO4GZ5V%SI2W6K6>H-=7"FT#!(%V^62
MPP6(*DYQQD$<$^IJI>>&K>[\36FOB\NX+RV@:W41% CQL<E6!4DC(!Z\8XH
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M6B1M(Q Z%CM &>.<\XP0#>HKSK4O%NNV#:IIZR6S76G:I8VXN'A.)H+AE R
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M&HP>;%NVR;I 0<$9&(Q^?X5!I^MZ[)JVGV=U>V[)JFBO>H8K?:;>5/+Z9)W
MB3N.H].* .ZHKR_0=7\1?\(_X&MX-3@,FLPR>=-<6V]D(@:0'AAGD9YZ^M:%
MYXCUS3M.\9K)=P37.AV<4T,H@"AW,)=LKD\%AP,Y [GK0!Z!17%7>O:YJ-UJ
M5EH<?^F6%M"Z@K&4DED0N ^Y@0F,#Y>>ISQBM[4[W4X/"TM[9V8EU(6X<6R,
M&^; R%.0&(YQZX'K0!KT5YEJ7B.XU?0;:73M:E!&OV5M(DEL(KB)6DC!CE4@
M8.[)X !&!TSG1U[Q+JVDW-P\5U!.EK>V=L8HHMR[)6C5S*W&V0ER552<#:2,
M&@#O**\ZDU[4-%U;QK?379N8[2YM+>WA= %3S4CV]QPK2$GD9YYJ;7]:\6:%
MHFO7NV$0V]NDUG-=(ADW9PZ%8VP1R"&[9P0: ._HKB9[_P 2?\)5?Z&FJ6B@
MZ<M_%/\ 8\F([V0H!NP1P#D\]?7(K:9XNU3Q!9Z3!:QF&]NM&CU&5H$C;#L=
MH $C#Y00<]3R.1UH [^BN%@U;Q7=Z_I^CW$UAI]Q/I$ES/Y</G>7,DB(=IW8
M(^8\=N^:S]/UW5]?O? 5V]X+?[=!<R7$,48V-(B8W<\\Y.!VS0!Z537=(XVD
MD95102S,<  =S6'X@UJ6PU+1-*MR(YM5N7A\YAD1*D;2,0.A8[0!GCG/.,'C
M_%6KZE<^$O'FC7,X\[2K?*W*1@>?#+$6"L.@8<@D=>.!F@#T#3]9T[5);B*R
MNDEEMROFH,ADW#*D@\X(Y!Z'M5ZJ$$;V>EM,\D,EP(<M-(HC!P"1N(Z 9_G7
M,^'/$>I7GB6VTZ[F2XAN=(%\95AV)YH=5;RNA,9W\%ADX!R<T =K17+ZYJ6K
MQ>,-'TBQNK>"WO[6ZD=W@+NC1^7@CY@#]_ICMWZ5@6'BCQ"VFZ%J5U=6CI/J
M[:5<0I;E?, EDB\P-N^4Y0' XZT >CT5PK^)M4A\0:=%Y\$]O=ZO-8.L,>8H
MT"2,F'."9!Y?S 94'(X(JAI&O:GI]A=F:[DO+B\\23Z;$S(@*;6?D9(&=L>
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M@ +@@GYCSC% '<T4 Y&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5-/!^B1VL%LMDHB@OSJ,8S]V<L6W?^/$ >F!5H^(-,$!E-R5 G%ML:)Q(92
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MB[LEN)(E&W<< MCMQD9 Y%;<6OZ7-J*6"7:&YDW^4I! EV_>V,1AB.X!..]
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MOO!FCZAI1L)TF!^T_;!<QRE)UG_YZAQR&[>F.,8XJ=O%N@*MLW]JVS"ZA,\
M1MQD0=2H')ZX^O%-MO&'A^\DLH[?58)&O3BWVDX=N?ESC ;@_*<'@\4 $/AF
MWMH[<07NH)/"7;[0T_F22E@ =Y<$-PJ]1Q@8Q@5>LM*M=-TB/3+)6@MXT*)M
M.2,]3D]\DFHI=?TJ"^CLY;Q$FDD\E-P(0R8SLWXV[L?PYS[55A\8>'KBYAMX
M=6MY))IC;QA22#("1MST!R#CUQQF@"*S\':;8IHL<$MT$T;=]C4R [0RE2#Q
M\WRDCFGV?A'2[%HTA$WV2&X-U#9L^88I22=RC&>I) S@$Y '%%CXNTR^N=5B
M#2Q#3KD6TCR1. [83A>.22X4#J>V<BM6RO[;4(Y'MG+"-S&X9"I5A@D$$ @\
MB@"KINA6>E7M_=6IF5KV8SRHTI*!R!N*KT&<#-4KOP;I5WKLNK%KN&:X55NH
MX+EHXKH+POF*#AL#CW'!R*DD\9>'8Y&1]7M@5N/LKD$D)+Q\K'H/O 9/&3BI
MH/%&B7,=])%J4!2P4-<LQVB-2"0QS_"<'!'!QQ0!!<>$M,N+J_E/GQQ:C@WU
MLCXBN2!C+#'&0 #@C<!@YHN/"EA<SZM*\MR#JMNMM=!7 !C4$ #CY>&89'K]
M*N0Z]I<\5Y(MVB"R -R)@8C""-P+!@" 1SD]:P[+Q.]UX[O]/^TH--M],CNB
M)(3$T;%V!+%L'&U0<\#F@"\_@[2I98))1<.8K$Z>1YQ E@/\+@8SBH]/\%:9
MIMU:74%QJ!N+6U:TBDDNF<B(XPN#P<;1CCMSFM2QUK3M1NIK6VN UQ"JN\3(
MR.%;HV& )4X.".*M7,R6]M+-+*L*(I9I'Z*/4T 85EX,TW3UT=;>6Z5='#BS
M!D!VAQA@>/FX)'-:.CZ+;:)#<16KS,L]Q)<OYK;CYCG<Q''<G.*SK3Q1I-KI
M>F"^UZVN9[JV\V.94V&Y '+J@SC/I[X%;&G:C9ZO817UA<)<6LH)21.AP<'\
M001CVH PE\!:,LL;J]\JQ7S7\,:W;A(I6W;MHSP"7;(]S4G_  A>F_8Q:^?=
M^4-0_M+_ %@SY^_?NSCINYQTK,@\171TWQ2VHZS;:?\ 8-4-I;W;0 K&GEQ,
M!LS\QR[#KWKI=0U[2]+:1;V\2+RD$DI()$2$D!G(&$4D'DX'!]#0!EVEC<:M
MXHCU?4='^Q-IJ36]H\DJ.\V\C+C:?E7:O //SG@8YV=6TNTUK2;K3+Z,O:W,
M9CD4$@X/H1T-<S<>,8K+QCY5QJ-O_8CZ3]KC9$W$OYFW((R6X!. /7TK4F\6
MZ9'JVDZ?&[SMJ<+3P2Q1LT9C 'S;@"#G<OT!R<<9 (#X(TQY+J66YU":>ZL?
ML$\LMTS,\66)![9^8C...V#S5N#PQ96]]I]XLMPTMA:M9P[G!'E';D$8Y^ZO
M/7BM*\OK:PB62YE"!V"(,$L['HJJ.6/!X'I6!XA\96>F>#[[6["1;EH<Q(NQ
MCMESC:X RN#U!P>W>@!]EX(TO3QI0MI;U5TIV>T5IRPCW*5(YSQM)7']>:=J
MO@K2M7NM0GN'NT&HVXM[N.&<HDH (!('< D59L9[FSL[V^O]1:[L1^]A)M"D
ML: ?,&"@;N0<84''K7//XY^TW/A*_@F%MI6J"5KA)H2'X@,B@,??'0<GH30!
MJW?@?2;J_M[U9=0MKB*!;=Y+:\DC:>(=$D(.6'7GK[UM7FFP7FG&Q)>&'Y=I
M@;8R;2"NTCI@@5!;^(-*NM+BU&WO$EM96*1LBDL[@D%0H&XL"#QC/!JQIVI6
M>K6@NK&X2>$L4W+V8'!4@\@@\$'D4 95SX0TR]M[I+EKB2>YGBN)+H2;)?,B
MQY; J !MVC&!Z^M5KKP#HUV;S>]^J7<L4\L:7;A3+'MVR8S][Y%R3UQZ\UK'
M7]*&H1V)O$$\DC1("#M:11ED#8VE@ <KG/!XK/M?$VE6UG+<WOB"TGADOWMX
M90HC"MNP(NIW%>A;^5 $EQX.T:ZGU-[B&65-3B6*[A>9C')M4*&QG[V !NZ\
M9ZU67P+I9T.ZTF>ZU*Y@N4$<CW-VTDGE@Y"*Q^ZOTQGO5W_A+="_L]+\:@C6
MKQM+YBHS;44E6=@!E5!!!)P!BISXATH&['VQ#]CA6>?:"=D;9*OP.5(!Y''!
MH C;P];MJ[ZH;FZ^UO:"S9]RX\O)/3&,Y).?Z<5F/\/M&-GI<$,M_;2:9&8;
M6YMKEHYEB/6,L/O+P.M:,_BW0;=E634X-[6PNE1<LQB.,, !D]12VGBK0KZ\
MM;2UU."::ZC\R (<B08W<'H3CG&<XYQ0 D?AFQ@U2#4()+B*>"T:SCQ)D"-B
M&.=P.26 .XY.1]:JVW@K2;2VTF")KM5TIG-JPG(90X^921C*GWJ[)XETJ-9F
M^T.PBADG.R%SO1" Q3 ^?!('RYZU6L?&&E7FB:?J3R20B]@$Z0F)VDV[0S':
M!DA0PRP&.>M %[6-%L];@ACN@X>WF6>":)MKPR+T93^)'H02"#52Z\*:=>Z3
MJ&GW#3NFI'-Y-O DG^4+@D#@8 & !@"I)_%6@V_V;S-4M\W,'VB *VXRQ\?,
MH'7J,>N:FCU_2YM-MM0AO$FMKK_4-$"YE/)PJ@$DC!R ,C!]* +#V$,VF/I]
MR6G@DB,,GF'ET(P02,=C61I?@S3-)O[.]AFOI+BTMC:1M-=._P"Z)!"D9P0-
MHQ_C5Y?$.E2:?#?Q7BS6\X8Q&%6D9]OWL*H+<8.>..]-;Q+HZV45Z+Y)+:6$
MSK)"ID'ECJYV@X4=R>* 'W>B6]YK5GJSRSK=6<<D<.UAM ?&_(QSG:OY5G)X
M+TV.PM;)9KL0VMZ;^(>8,B8L7W9QR-S,<=.:V;[4;33=/DO[R816L2[Y)2"0
MJ^IQT'O4$VO:5;SR037L44D=M]K8/E0(<@;\G@C) H R5\!Z,DL3JU\JPWS7
M\,:W;A(I6W;MH!X!WMD>]/N/ NB75GJ%K-'<&&^N3=LHN&'E3%MV^/GY&W<Y
M'\N*NZ?XHT35;N.UL=1AGGD@%PBKGYX^/F!(YQD9'49YK'U;Q7M\2>'++3;R
M-X;V]D@G'DDB15BD8['/RG#* <9ZT 73X,T]K.UMY+K4)6M[E+L3S7)DE>5/
MN%F;.0.R]/:K5]X:L-2U1K^Z\YY'LY+%TWX1H7P64C'<@<]>*E/B'25ODLFO
M8UF<NJ;@0KLGWU5B-I*X.0#D8/I4>E^*-$UJY^SZ;J4%U+Y9EVQDGY VTG\^
M/R]: *=AX*TW3KJVNH+C4#<6UHUG'))=,Y$1Q@$'@XP,<>_)K4T71[;0-'MM
M+LC)]EMEV1"1MQ5>PSWJ&?Q+I%JVH">]5#IRJUWE&_<JW(+<< @$Y]!5'Q1X
M@^P^&-2NM.N%2^BTV:^M_,A9@51<Y(./8<^HXH 23P3I<UC?V<DMXT=]=B]D
M;SL,LX*D2*0 5(*+P...E-F\!:'<0ZG%<+=3#4C&TYDNG)WH %=3GY6&U>1Z
M>G%6M'\3Z9J,(A&H0O>16J3W"],*1RWH1G()' /%&F:U:KX?L+JXU9-0-PI\
MNY@@(-R1DDI&N3T';/3- $;>#M-ET633+B:^N!))'*US-=,\^]&#(0YY&"!@
M#CKQR:T[W2;+4M'ETJ]A^T6<L7E2)(Q8LON>N>^<YSS7-7WC"*'Q'H#P:C;/
MH>H6EU,71-Q9H_+VX(Y/WR-H&<BNIT_4+35;"&^L;A+BUF7='*AX84 9J>&+
M012B:XN[B62U-GY\T@:1(3U4''?C)QDX&2<"M#2].ATC2[73K=I&@MHUBB\Q
MLD(HP!GO@ "JQ\0Z6'=?M)^1'<D1.5*H<.5.,-M)YQG%20ZYIEQ-8Q17:,]_
M#Y]K@'$T> 2RG&#P0?Q% %%O".EF>[8"9;:\G%S<V8?]S+*"#N(QD9*@D @'
M'(/-%SX1T^[.M>;+<XUF,1WBB0 ,H78 ./E^7CC^?-61K^G75Q]AM;^(7<J.
M8-R$K)MX8H> ^T]=IXK%\$^,K;7-#T>.^OX6UF[M?.>)5V[B.6QVR!@XSD#F
M@#67PU:IJ=OJ*W-T+FWM#9QOO7B,D$C&,$Y53GVJM;^"M)M;32+>)KI5TDM]
MD83D,JL,,I(Z@CUK9O+^VL1'Y[L&D)"(B,[,0,G"J"3@5E+XNTR37;#2X6EE
M:]M#=QRI$Q39E O.,<[_ ,,<XR* +NLZ+::[:16]WYJB*=+B)XI"CI(ARK B
MJ4WA#3)KB]D!N(X[]%CO84E.RY"C:-^<G.W@D$$CKFK%OXFT>Z9EM[P2L(&N
M%"QL?,B!P73CYQG RN>H]:KZ3XMTW5M M=70RQPW7^JC,3EVXR J@98[>?E!
M[^E &I>V$-]I\EDY>.)U"YA;8RXZ;2.F,5E77A#3;ZUOH;MKB:6]:%IK@N%D
M)B(:/!4 #:1D8'KG-3?\);H'E6D@U:V*WBNUOALF0+G=@=<C!&.N>.O%1P>,
MO#MR;00ZK YNY/*AQGE\D;3Q\K9!&#@DB@"I>> =&OFOC*]^%OA$;A%NW =X
MPH5SSRV%7GOCUYJW+X1TBXN[Z>>*:47]NMM=1/,Q2554J"PSRV"1GKWZ\U;N
M=?TNTO$M+B\2.5Y5A!(.WS&&50MC:&((PI.3D>M5?^$Q\._:! -6MC(;G[+@
M$D"7CY2>@R2 ,]3QUH ?H/AFS\/1E;>XOK@[1&C7ERTQC0=$7=]T=.G7 SG
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M]"2]BBEVW%L)4C*_/AER 1Z\U;EBCGB:.5%DC8896&0?J*?0!YMX?TC4[/\
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MW(SVKT>**.")(HD5(T4*J*,!0.@ JKJNKV.B:?)?ZC<""VBP'D*EL9X' !-
M&)XHLK_^W?#FLVD#W4&G7$OVFWCQO*21E-Z@]2N>G7!.*YS7/#^I3Z#XRN+6
MQG:36KF![6S4 -A%C4N03A2VUCSS@#/)Q7I$TR6\$DTA(CC4NQ )P ,G@4RT
MNH;ZS@N[=BT$\:R1L5*Y5AD'!Y'!Z&@!LX-UI\JHI#2Q, '&""1WKSW1=-U6
M*#X?1W.CW<)TB-X;LN%.P_9S&&X8Y!8\=\<X KTJB@#RL:1KEG$NHQZ3>3I:
MZ_>W4EE%+Y4LMO,6VR1D,/F&[.TD'DBN[\-6L5OI\TL6E/I@NIVG,,K!I68@
M9>3#,-Q(SU/&,\YK9HH X3PI#JMA!!X?U/P_)+)8W<DL>IR>6T#(79A(ISN$
MA#$8QU)R<5EMI&J'3&C.E71;_A+?[1V;1_Q[^=OW]?3MU]J]/HSSCO0!Q-^F
MIZ5XUU"[.AW&L:7J]G#!B#RR87C+@HZNP&QA(3GUSQ5+4].U6UUC6S#HTDR:
MEH,5K";3;Y44L8E!0Y(('[Q<<<CWXKT.B@#@?#]AJ-GXAT2ZNM,N88[;PVMG
M*Q"MMF#(=GRDYX4]..W7BJ&C:-JEKH?@*VETRX273+QWNUVC]RICE7)P>>77
MIFO3:* /.M(T35;:ZD@L([R'3+FRN!/87X#"SF;&T02=2K'/RY( '8X%1Z=;
M:W'IGA:SG\/W<<=OI;6<\D1B$Z2A8UVE]V4B;:Q)4@DJO;KZ310!YGX8TK5;
M.7P,;S2;J$:9I=Q;718*WENPB"_=)Z[&Z>V<9J#2M.U[0K?P]J8T:[N%L9]1
MBNK*/;YJI/-O21 2 V !D9SAC[UZG10!Y]J=IJ5GJND:W!X=N6L1#<07&G6$
MJQSV_F.KB3"NJL25^8 ]3WQFH-3\/3)9V[Z/IU_HM_!:2&T-IMEC)=V;[/.A
M)4@G!)Z EOF]?2** .?\1Z??ZO\ #_4].$<?]HW6FR1>6APGFM&1@$]L\5S)
MAU:^UI;_ /L&_A@/AR:R_>[ PF+*0NT-WP1_@.:]&HH \VMM%U5HO!,"V=Q;
MR66C3V=S-M&+>5H8T7.#S\R'D9Z U%IMIK?V'P/83>'KR*;0[E8[MP8_+VK;
MR1;U;=\P)(/_ ->O3J* /./#&F7EJ+/2-8\.7<USI=PTD>I23[[9E!8K*@WY
M$A4XVA>I.>*Z#X?V5UIWA"WM+VTDM;B.>X9HY ,X:9W!XR#D,*Z>B@#C_$/A
MV[O?$\$]H@-CJ=HVGZM\V,1 [U8>Y!D3/;S >U9D&@ZW%\-M=L+Z)KG4CI\V
MEV80@M+$BND3'T+;LD^F,]*]#HH XFQL[R'Q?H]\UA<+;0:"]K*^S[LN^-@F
M.O1&Z<?G6%H>GZ]X<L/".H-HMW="QLI[&]LHBGG0EW1ED4%@&^X <'H:]3HH
M XDV-U_PEOAB]316M+2UMKWS8XD7; 93&4!"G&X[6SMR,GJ>M:'@&SN]/\*1
MVE[;26TZ7-RQCD SM>=W4\<?=85TU% 'G>F:)JL&HO%IZ7D&FW4%S]JL;X!D
MM)6'RF"3KM9B3M!( ZX.!532M-UN<>"[=]&OK3^S--GL;J9S&/+D,,<888;E
M<J<'J?2O3Z* .&\(G4K?2=+TO5/#,D%UHUM]G:\81NC!4V P$$L2^%)X'&0>
MV<S0-&U2SL?A[%-IMQ&^EF87HVC]SNA=!GGG+,.F?6O3** .7\7Z9_:+Z?M_
MM*WFA,CPZAI_+VSX &Y.=ZL,@C!Z#IU&/9V?B.#6O#^HWNF+/<C1Y[.X\G8D
M<<K/&R[QG@$(<[<\\#M7H%% 'FGAW3]9'B'PY>W6B7EL(M,N+2Z!\I(K>0F(
MA416PL8V,!@9(QG/6J>GZ7KVE:!X0GET*_F&D6\MC?6<$ZI,P8)B6/:X# &/
M&"02&Z5ZO10!P4>D2Q:]X5N;30I;*TAGNYYXP0QA\V,J"Y!.69CDX)QGD]ZS
M9-'U0^'+V!=+N?/D\4#4$3:,F#[4LF_K_=!XZ]L5Z?10!YS;:7>QZMJ6DZGX
M=N]0@N=1>]M+S[1_HH1WWCS%+@JR'H I)P,>M5[[1]4E\-^*+:/2[EI[S7X[
MNW7:,R1"2!M^<\<1MP<'IZUZ=10!P-WI=T^K^+DNM%O+NPU06LD;0R*A9514
M8*=P8.I!(Z=!S6QX/M=6LTU""_N9[NT69?L5S=QA+B1-@SYF ,X/ 8@$X],5
MTU% '"Z]X1N]5\0ZE:Q_N]&URS7[?(K89)HN$*^[!D_"(^M07.B^)+SP LUS
M"LOB$3VUU-;K-L$OD.G[L/\ P[@A;V9S7H-% 'FNLZ;-J_A?49[+PM?VMW>3
M68=+IU>XF$4RNV[YV&U5! R<GGCIG2\10:A:^+K?5TTF_P!3TRYL!:2Q6,WE
MRPN'+!BI=058,0>>-HKN** *&BV<>GZ-:VL5G'91QIA;:,Y$0Z[<]\>W%7Z*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *YKQGJ.HZ9:Z2^G7*0//JMM:R%H@X9)) I'/].?I72U
M0U71;'6H[>.^CD=;>=+B+9,\>V1#E6^4C.#SS0!P>IZOXDL;7QF(]=9FT!%N
MK>1K6+=*#")/+? QMR",@!N>O%6/%7BC5;"TU.^L+P$V5M;3BVAB5EC+'+><
MSC^($ !#D#G'(-=1<>$M&NO[6\Z"9O[60)>C[5*!*H7:!][Y>..,<56N_ ?A
MZ^-U]HM9V%U D$ZB[E"RJ@PA8!L%@.C'GWH PO$>IW>MZ=XZLX;QK6'2;-H1
M&B(3*S0>8Q?<"=I#!1C'0G/3"6>IZUJ%O_8VBSBVN+'1[26-B4^>21&P6#*V
M4&P#Y<'D\]*Z&\\$Z'?7$\\D%PDEQ;?9;@Q7<J>?& 0!)AOG(!/+9--N_ N@
M7CV,CVTZ2V4(MX98;N6-_*'_ "S9E8%E]B30!M:?)<2Z;:R7?D_:7A1I?(;=
M'O(&=I[KG.#Z5S6IW6LW'CQ-$M-5-G:2Z5)<Y2W1W21944$%@1_%W!'7C."-
M:WT&&V\2/JT):(&T%KY*RL48 @J=GW5VX(&!SN-3RZ%83:R-7=)A?"W:V$BS
MR+B,D$C:&QU .<9XH X[PUXLU+Q(?#^GRW)M)[O1WO[BXA1=SLKK& H8%1R2
MQX].E4/[7U?6+WPY#=7\UO/;:_=Z=.]NJ*MQY44NV3:RGG@<=,YXZ8[*'P;H
MEM::?;VUO- -.W"TD2XD\R(-]Y0Y;)4^A)'3T%3S^%M'N+.SM7M66.SG-Q 8
MYG1UD.[<Q<$,2V]LY)SN.<T 4_&^I:AI6B6]SIMPL,QO[6%BT8<%9)D0C!]F
MKG;_ %+Q';R^,+6/7F_XD]I'?6\IM8B[%HW;RV^7&S,?INY^]QSV^K:-8ZW:
M):W\;R0I*DRJDKQX="&4Y4@\$ _A56;PKI$\VIRR0SL^J0K!>'[5*/,0 @#[
MW'#$<8ZF@#%BU_59_$FG0QRPB"[T"2^$#* HF#18);KCYS6-+K]QJ?A'Q79:
ME->PZE!HDK3Z?>P(C1MY;AGC9  \9. ""<8]Z[$>$M&$T,WD3%X;-K&,FYE.
M(&QE,%L'H.3SP.:5O"FDRVUS!/'/,MS;?8Y&EN9&<P\_(&W;@.3GG)[DT <W
M!JFKWVS0](G^S7%KHUK<1OE,N\@<#(=6R@V#.,'YNO2JOB/Q-K^FZ+J-XM]
M;[3],AN9;>Q19(TE^8N9&<?<; "A2&QDXZ&NFOO!&A:@UB\MO<)+8Q>1!-#=
MRQR"+^X75@S+[$FB^\#>'M1>Y:>R8+=6RVL\<4\D<<D:@A045@I*@G!QD=J
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M;L#)PN<<GCDUD:UX69M;\/-I]G.UM;WTUW>3I<!7W/$R;LE@Q.2O'3 QTXH
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MJIIFG6^DZ=#86@D$$(VIYDC2-C.>68DGKW-6Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JAJ^M:?H-B;W4IS!;!@ID\MG )(
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M[<CZT ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX'!/8'J*O6UM!9VT5M;1)%!$H1(T& H'0"I:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9+*D,3RRL$C12S,>@ Y)
MH ?14=O,+FVBG5759$#A7&&&1G!'8TQ;N)[^2S7<98XUE?C@!BP'_H+?E0!/
M16#<^,='M=1O;"5KPW%E&LMPL=E-((T.<,2JD8.#T]#6M8WUKJ5C#>V4\<]M
M.@>.6,Y5@>XH L45G:UK5GH&G_;;[S1#YB19CC+_ #.P5<XZ#)')K1H ***:
MSJI4,P!<X4$]3C.!^ /Y4 .HJM?W]II=E+>WTZ06T0R\CG ';\\\8[U1'B.Q
M$ELDT=Y;FZD$<!GM70.QZ#)'RGV;!H UZ*** "BBB@ HK'E\3:=%>ZI:/Y_F
MZ9;I<W $#'Y&W8*\?-]QNE7].OX=4TRTU"VW>1=0I/'N&#M90PR/H: +-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%96O?O[6#31UOYE@8?\ 3/EI,_5%9?JPK5K.U*SOIY[>?3[BS@FB5U+7-LTW
M#;>!MD3'W??\.X!RUWJ]]8>+UCU+[6NGW-_'%97MK+OA!*A?L\T?\)+YP^#D
ML.0.*Z70O](AN=2/_+].9$/_ $R&$CQ[%5#?5C60?#&JM=O<F[T;S7D\UO\
MB73;3)C&_;]HQNQQNQD5>AL/$EO!'##J>C)%&H1%72Y<* , #_2* .+UFXUR
MT\<>,+C08XI;F/2[)FB:,L[+F7.SD#>!D@'()P*NVEW8:#X.\&:9X=NY&TC4
M+N.U^V$_/L97<C/\+,XV^V3C! K<A\.ZO;ZK-J<5[HRWTX"RSC3IMS@= ?\
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MD2O>RDS3 !<1J0 % &!D^^"1G%3VW@*2STRXTVW7P]'97!!FA72I<28Z!O\
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MG)B#DE8_^ J0OU!K3JK8)?QPL-1N+:>7=\K6\#1*%]"&=N>O.?PJU0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYC2LP8^Q4J0>]6]0U);GQMH^CK*\6EW=M=3;H':/S[A&4;=RX/ +MP>3SVH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>DVFG0ZN8?+BN9K?/3H&*X8K[9I^CZ?+86TC74L<U[<R&:YEC0HK.0!P"20
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MD'G@C(/K0!T5%<9<>.FEAT2;3M+N9$U#4I;"19&C5T:/S-P W8))B.#G&/?
MI\WBFQTA_%-^;'5IFTV2,WL0=7 'E AHE+X"[<$XP>IQ0!V%%8]YXDL[%7DG
M206\=H+N2<%2B*3A5X.26(., @X/-0Z1XLLM7UFYTE(WBNX(5N-I='5XV)&0
MR,PR",$'GIU'- &]17'?VC<:]\0]0T+SYH-.TFUBDF6"0QO/++DKEU(8*JCH
M",D\\#%,BU6[T/X@'P]NN+VRO-/:]M4DDWRQR(VUD#N>5(((W'@Y&<= #M**
M\B_M?5)/ %KXI U9-0N72"1ENE\EUEN57(3?P0"54@ @GTYKJ=/FTS1/%5W'
M-)K,$ATY[]UO;SS;>"(,H8*-[8((SWQDX.#B@#M**YY?%ULA9[RQO;.U%DU^
MMS-&#&8EQG)4G:V"#M/.#ZY%4I/B%IL+W\<EK<^;9V+:@4C>*0R0K][!5R R
M]U)!YXS0!UU%9FBZPVLV[S_V=>6<7RF)KD*/-5E#!EPQXYQS@^U:= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK6B7$-O81V&G-,SVK0C$AD7;P ,#'7H<^U '(Z==/9[-&N]0NY[9=>N8-/\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>elicio-ex312to10xk_aapri001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 elicio-ex312to10xk_aapri001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8A(I"3^Z"DX*^A^8Y(YZ4 =]17F_A+0K&7X;Z;K#1?Z7)H;1S'M-N56W,.[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44=*3<O\ >'YT +12;E]1^=&Y?4?G0 M%)N7^\/SI: "BFB1"S*'4LO4
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M#T_3VD\QK6VC@+_WBJA<_CBKM-:1$959U#-]T$\GZ4NY?4?G0 M%(&!Z$4M
M!12*ZN,JP8>H.:-R_P!X?G0 M% .>E('5F*A@2O4 ]* %HI-R[RFX;@,D9YQ
M1N7>$W#<1G&><4 +12%U#!2P#'H,\FEH **** "BBB@ HHHH **** "BBB@
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MZXCN8P\(661T^Z9'!P>N3A5SW[YO6V@[%U+[9+#>O?2-(6EMQ\H*A=N,\J
M/7KSS0!R'CK5[/Q/\"[[68%5H[BR29 >3&VY<CZ@Y'X5PVFRQ:IJOP[TGP_"
M=-UNUM(+J^NF40">#8A8 ]9MP#<<]_?'H-A\+DT_P)?^$$UNX?3[MRVYX07B
M!()"G.,$C/(/4^M37_PQM+[2O#\"ZE/;:AH(1+/4((P)-B@ *P.0>@/Y^IR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4%<+PQ#M[<]!BK-AI&H6&LVI34;F338+ 6S02!-C.I&UQ@9W8SGH.F!Z;U%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:C;+<V5S#<P,642PN'4D$@X(XX((_"IZ "BBB@ HHHH **** "BBB@ HHHH
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M7S337-[<(D<EQ/MW;$SM4!0  "S'@=2: .'\>:U#J>E>%]1T:,WQ3Q!#Y43
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY4J""< Y.#TH [^BN$NM?\1Z/IJ2ZQ:S+;I>2I/=642S2I;[<QR-&I8#DX;
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M[>99X)HFVO%(O1E/XD8/!!((-5+KPIIU[I.H:=<-.Z:D<WDN\"2?@+R0.!@
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M@71+JSU"TECN##>W)O& N&'E3%MV^/GY&W<Y'\N*NZ=XGT35KM+6QU&&>>2
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MBW2KQO$.E7NER+'/?A]+O!G!-NRL^]?]I-K$?[QKK)K8?V=):P(J+Y)CC4<
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M+Z>-I8HMI^95QN.<8XR._>J5QX4T>YU*74##/%<S$&9K>[FA64@8&]48*W
MY!X% &!9HUSXOAU:TL+O^S#H/V6-WCP0_F;O+(/.<#GMGO6=X>TC6-.7P#)-
MI=P3I^G7%E=J"F8781;2<MRO[MN1GM7H\44<,211(J1HH5448"@= !575=7L
M=$T^2_U&X$%M&0'<J6QDX' !- &)XHLK_P#M[PYK-I ]U!IUQ+]IMX\;RDD9
M3S%!ZE2>G7!.*YS6_#^I3Z#XQN+6QG>36KJ![6S4 -A%C5G()PI;8QYYP!GD
MXKTB:9+>"2:4D1QJ78@$X &3P*9:74-[9P7=NQ:&>-9(V*E<JPR#@\C@]#0
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MK_=!XZ]L5Z=10!YS;:7>QZMJ6DZGX=N]0@N=1>]M+S[1_HH1WWCS%+@JR'H
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MU*GGQ@$ 28;YR 2,G)IMWX%T"\DLI'MITELH1;Q2PW<L;F(?\LV96!9?8DT
M;6GR7$NFVLEWY/VEX4:7R&W1[R!G:>ZYS@^E<UJ=UK-QX\31+3539VDNE27.
M4MT=TD65%!!8$?Q=P1UXS@C6M]!AMO$CZM"6B!M!:^2LK%& (*G9]U=N"!@<
M[C4TNA6$VLC5W287PMS;"1;B1<1D@D;0V.H!SC/% ''^&O%FI>)#X?T^6Y-I
M/=Z.VH7%Q"B[G<.L8"A@5 R2QX].E4!J^K:S?>&X;J_FMY[;7KO3YWME14N/
M*BEQ)M93SP..F<\=,=E#X-T2UM=/M[:WF@&G;A:21W$GF1!OO*'+9*GT)(Z>
M@J>?PMH]Q9V=J]JRQV<YN(#',Z.LAW;F+ AB6W-G).=QSF@"GXVU+4-*T6VN
M=-N%AE:_M8&+1APR23*A&#[-7.W^I>([>3QA;1Z\W_$FM([ZWE-K$78M&[>6
MWRXV9C]-W/WN.>WU;1K'6[6.VOXWDACE29525X\.A#*<J0>" ?PJK-X5TBXE
MU.66&=GU2$07A^U2CS$ ( ^]QP2.,=30!BQZ_JL_B6PACEA$%WH$E\(&4!1,
M&C );KCYS6--K]QJ?A#Q99:C->PZE!HDK3Z?>P(C1MY<@9T9  \9. "">GO7
M8CPGHXFAF\B8O#9M8(3<RG$#8RF"V#T')YX'-*_A329;:Y@GCGG6YMOL<C2W
M,C.8>?D#;MP')SSD]R: .;AU35[XKH>CS_9KBUT:VN(WRGSO(' )#JV4&P9Q
M@_,>>E5?$?B;7]-T;4;Q+Z WNGZ;!<2V]BBR1)*=Q<R,X^XV %"D-C)QT-=/
M?>"-"U!K%YK>X26RB\B&:&[ECD$7]QG5@S+[$FDOO WA[47N6GLG"W5LMK/'
M%/)'')&H(4%%8*2H/!QD4 8NN:G>:ROC/3X+QK2+2;()M1$8RN\)D);<#\N"
M% &#PW/3":'J.H17GA#2XKH)9W?A]I63RP2)$6$*V>O\9XK=NO!6B7=R]P\-
MPDLEM]EF:*[E0SQ@$ 28;Y\9/+9/-30>%-(MI[">&&=9+"V:UMF^U2GRXCC*
M_>Y^ZO)YX'I0!Q_A_P 1>()H/!VH7NIK<)K$TMM<6XMT11A)75P0,ALQ@=<8
M/3/-6(==\17\U@L%PT5Z^KS6M[9"!66WME+XDSC/18SN)P2Y [ =);^#M$M+
M?3((+:98],D:6S7[7*?*8@@GEN>&8<YZFN5TKPGJB2CS+._TZ^\YII+NVUJ0
MVI=G+,RP[N023\A4#L3WH Z;QK>ZCI?AV35=.G=/L,B3W,:HK&2W##S0,@X(
M3<01Z5@P^*+Z?Q#K&DQZA(WVD1/HTPCCP5+;)2/E^;RV!)S_  _F>]EBCGA>
M&5 \<BE74C@@\$5GVWA[2K1M,:"SC1M,@:WM#WB1@H('U"CF@#CO$FJZL(O'
MMB-2ECCT_1H[FU>)$5T9DF+<XYSY8^G;%-^QW<GC#PS;P:G-%,V@W/\ I)CC
M9U&^#H-NWTZJ>/?FNPE\,Z3/=ZE<RVSO)J=N+:[W3.5EC ("[<X'#-T ZFHK
M;PII-I=6EU%'<^?:6[6T,C7DK%8VQD'+<]!R>>!Z"@"+P5JMYKG@W3[^]=6N
MY$99)%7 9E=EW8[9VYQ7*67B+7X?"_\ ;MYJR3"2^?3EA-NB(A-YY*REO55S
MQTZ9[D]YI.C6.AZ8FG:?&\5JA8JC2NY&XDGYF)/4D]:J1>$]$BT&YT/[&9--
MN6=I8)IGD#%VW,<L21\QSP>O- &'=W/B_38-1.!?1B2![:.-XC=^5G]\ -JH
MQ !*\>HY.*ST\3:CJ<_AZ+2=;?RK^^NK6X:XLE6:+9"[['4@;74@=L'@\C@]
M1:>#M(LK$6D*W>!(D@E>\E:4%<[?G+;L#)PN<<GCDUD:SX69M;\/-I]G.;:V
MOIKN\G2X"ON>)DW9+!B<E>.F!CIQ0!F6?BG7+>\?P]>W*W%ZNLFP74%1(B\?
MV?SUXP4$G1>F.>F:OQ:MK]GJ6FZ%JMY L]_>SK%=Q;&D$"1[U5AM""0DX^[C
M )QFMV\\(:)J&D2:9=69D@DG^TLQD82>=G/F;P=P;WSTXZ<5'<>"M#NM'BTR
M>WF>**83I,;F3SUE'_+3S=V_=CC.>G'3B@#G]6CUF/6O"EI>:Z[R'5;B-GMD
M1=R>1*\>\%2-X7&> .<XZ$:?Q%:X3PW;FVO)[9CJ5FC&+;EE:=%(.0>.<_AS
MD9!TY?"FCS65E:O;RE+*;SX7%Q()!)@@L7#;F)#,#DG.>:N:MI%EK>G/87\1
MDMW96PKLC!E8,I#*0000#D'M0!S$FK:K?W/B:UL=1:VET-(XXM\4;>?(8A(6
MD!7[IR!A=O0GN,:MMJL^M^ (M70R64]WIPN08\%HF:/=QN!''N*FG\*:1/<R
M7!AF226!;><QW$B^?&,X$F#\V,GD\\D9YK6\B$6WV<1H(=FSRP,+MQC&/3%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %4-7UK3]!LC>:E.8+8,%,GELX!)  .T'&20/J:OUQ?Q6_P"2>WG_ %\V
MG_I3%0!T%OXCTJYOX[$71BO)5+1P7,3P22 =2JN 6Q[5J5P7Q;4'PM9_9O\
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M#<V45Y&X\B2,2J[<?*1D$YZ<5P>HWNH-;_$#3+N^>Z@L])0P[T12I>"4N?E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!Z53'FCC>-'=5:1MJ GEC@G _ $_A7F_P!LN=/O]'T&[\2K<V5R]X%O':1
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MC7Z[&N6B$T<,C)OEE'S?*NWIDDG)Z9 !WEWKD%GK^G:/)#.9K])7BD4#8/+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^0N]F'1B<9SR>:O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;\4Y9;7P!
M>W5O<7%O/%-;[9+>5HV :>-6Y4@\@D?C795S_C30;KQ-X9GTBUGA@::2)S+*
M"0NR17Z#KG;CKWH YJ/5+[0_$^M7UE'JMWX9L])^T3)<,[?Z2K$D1-,<D>6"
M2 <9]^*T;OQ(MY;Z//J.@7T,%SJ-LMG)]I4 LZ[E=@K9P,D;2.>XKH=<L+C5
MO#6H:<C113WEK)!N))5"ZE2>F3C.:R;_ ,.7]YHWAZS6>V672[FWN)&.[;)Y
M0Q@>F?T]Z *USX^%LNI3-HMW]ETR_6SNYC)'\F[R\.!G+?ZP<#M^5:5[XG:&
M2^^PZ9<ZA'I\R077V?EP[!20B8^<JKJ3TX/&2"!CWW@S4;O2O$MDMU:J=8OT
MNU<ACY041C:1W_U0]/O>W-J/PWKECK^HW.F:I:P:?JLBSW4,L+/)#+L",T3
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M]6AN-NBZ5=1VNI1Y^_YXP7/M'NB/_ F]*ZW4-76SOK33X8O/OKL.\49?:H1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"H88(!'O2@ # &!110
M 4444 %%%% !1110 4444 %%%% !2  9P ,]:6B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Apr. 09, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">ELICIO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3430072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">451 D Street, 5th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">209-0050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,704,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001601485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) amends the Annual Report on Form 10-K of Elicio Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;Elicio&#8221;) for the fiscal year ended December&#160;31, 2025, as originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;12, 2026 (the &#8220;Original 10-K&#8221;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company&#8217;s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. As used in this Amendment, unless otherwise stated or the context otherwise indicates, references to &#8220;Elicio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Elicio Therapeutics, Inc. and our wholly owned subsidiaries following Elicio&#8217;s reverse merger transaction (the &#8220;Merger&#8221;) with Angion Biomedica Corp. (&#8220;Angion&#8221;) that was completed on June 1, 2023. Terms used but not defined herein shall have the meaning ascribed to them in the Original 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_angn_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tewksbury, MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>39</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="angn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="angn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" original="angn-20251231.htm">angn-20251231.htm</File>
    <File>angn-20251231.xsd</File>
    <File>angn-20251231_lab.xml</File>
    <File>angn-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="61">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "angn-20251231.htm": {
   "nsprefix": "angn",
   "nsuri": "http://www.angn.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "angn-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "angn-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "angn-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "angn-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 39,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 41,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 61
   },
   "report": {
    "R1": {
     "role": "http://www.angn.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.angn.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "angn-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "angn_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.angn.com/20251231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r7"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001601485-26-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001601485-26-000035-xbrl.zip
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M4^4<.R] 6SU*9TF1S8_2L"$HE^,3TRR]*D?F=E&'C<6UR&0K>RO">SJP;^L
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M&!8B/1$$P&@SJIF!O >5Y:3Q4U#>DD[C%_D$.#2\)=,"#KC5!-8_]U$Q@.%
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M?1FE(34XQ*+$*C78R5ZHLW&4"YJL3""7)DW!!-=L<X2;;W/8F9-R&4RB8?Z
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MFUCUK"57498F:.%B7A+U\HTKA2M-E ^Y.Z@8PF;(:TFV/L0'52T=&+83V:^
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M7Q/KY GM(+>SU9@;6(;K=5"(7>545F6,PAI<F+0C]$['<R7SS=;9TME%;@#
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MW3UVVVV=J/ACT??4H7F1B=<4H"U=2ID<]!*>"9=Y'H/ZB:1G 269[;X13AG
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M2JFFY-Z=9-36B5*IH9P :2E55 50!?J<9G?[3MYMRO7-OV0FW/\-8RS<I>1
M=D($;R+GWF"?T2 Z19JF[S'E6OP-A%9")FFB\QOQ&V<BB.+"MAVY]CO.Y';>
M.>&,K$,BT/31JG<BU0CS7G$G*"TX$/TBA7DC\Q-Q,1*?R_F)JVDNQ21V$7W(
M9;KED]6-AR6KCPO)ZEO6V)JT+II>4L+ZE(T?G[2>Y>$HF;2NV,7?M?2'!W_'
M<-<B+F2Q4'S@TQ"#)=OEL([.Z^B\CLXK)M__Q&["P@CD&&Y.;SAV"<5X -R0
MQ2G^%P,"CKCYQ!!E.!E^E3U&4<%U6H!QAV+G+E,/@2_"@F"0@I! 7P ^'$4!
ML\GP!)602:ZZ9L$DM-$1'J"T'FNI:'N<"Z+<8<@<HY]1MG\0C(6#!_A7P=-2
MVQD?R-JTSA@^EY<:J+\(W3G5C;0DWXLD5TQF;G8%Y&HRWHLNY50?0(X]BIE]
M$)'<_Z9(OC?6^8S52G8G/N8?B [C>.-<!YVV:/OERV!D8WC1W!@HT24ZV]@(
M783B_^7<X[B-S_$,MFC3#8&#?T498)^:)X8'C_]T,N;.^3O?CO%&@M;C^&/
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M8)_;4SZ.)2/"7QOC.%42\MS.=?T[_'R:DT>H[I&.3<)C$L,FQ!HL3-1H/IF
MJHP\D'Y8NO&,M^?5R$E.&*:G!Z!X)'!8X<>[2D544L$* -1G%N,O:%)^Y2R$
MOU=8(0<FJ>["#Z6Z:U1&ZX'%\^7'RR79+%%Q" F=>!6S+R.XD)S,.=SVR/=
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M(,!*Y*W]:K(N-0:8']A;)O2]<.]MQ)Z8=3PJH_:Q%Z)FNI)I-JR6U6BW5S0
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M93<W.)$VXH54O.5<,IS.NCJ@E@N V7F S0%@F'!F\,D$'V;/,NRZ4W78==.
M?U[@E,F.U>RV=QO#>("!CH.FV;%4VU2OV;*4&WW9W]?HRXJC!5_\!,)73(_4
M7 7*2 -E%2AV&5!>R*19TF<N08#>^,%BW[A_DH&7ZA!&.H#6"+D=!T[D4(V
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MPT=D CY.#!\1H%3A[-I4KH*LMAHZDQ;#*HKA)5-Y%-F^%W(O C;8-5OWWX5
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M,?+F;]*-L5L1.[(NO/I%F/=^ U!+ P04    " #(@)U<%M;FS9X/  !JD@
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M4 W=3A@#3_/)0D5@( JE@?6:W%*4-UE^\\^R>*ANA_=9&04WC4) :2(%0J,
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MG4T)9F60:O!V==# TWR%D(K H!)2&MB70ILC7-^0JIL>)!PX0PB02WR@OH@
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M1E>#9YB__^S[43\G]KWZ#5!+ P04    " #(@)U<2.A'=],"  #C!   '
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MJRE.;%\@-BS+N"A<(YMAGQ!MPOCV,VB5CIW_@#E@N+$@NN(9^@ZT=,:.Y>-
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M,2YH=&U02P$"% ,4    " #(@)U<$7&W;=X"  !<"0  $0
M@ &?S   86YG;BTR,#(U,3(S,2YX<V102P$"% ,4    " #(@)U<%M;FS9X/
M  !JD@  %0              @ &LSP  86YG;BTR,#(U,3(S,5]L86(N>&UL
M4$L! A0#%     @ R("=7.R%:NFA"0  Z%4  !4              ( !?=\
M &%N9VXM,C R-3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( ,B G5P0<-XQQ0(
M +8$   <              "  5'I  !E;&EC:6\M97@S,3%T;S$P>&M?86%P
M<FDN:'1M4$L! A0#%     @ R("=7$CH1W?3 @  XP0  !P
M ( !4.P  &5L:6-I;RUE>#,Q,G1O,3!X:U]A87!R:2YH=&U02P4&      8
,!@"8 0  7>\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>angn-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="angn-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2026-04-09</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:SecurityExchangeName contextRef="c-1" id="f-31">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">true</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-33">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001601485</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39990</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ELICIO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">11-3430072</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">451 D Street, 5th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">209-0050</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">ELTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-18">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-19">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-20">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-21">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-22">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-23">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-25">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">81800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-30" unitRef="shares">18704798</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="c-1" id="f-37">This Amendment No. 1 on Form 10-K/A (this &#x201c;Amendment&#x201d;) amends the Annual Report on Form 10-K of Elicio Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or &#x201c;Elicio&#x201d;) for the fiscal year ended December&#160;31, 2025, as originally filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March&#160;12, 2026 (the &#x201c;Original 10-K&#x201d;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company&#x2019;s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. As used in this Amendment, unless otherwise stated or the context otherwise indicates, references to &#x201c;Elicio,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or similar terms refer to Elicio Therapeutics, Inc. and our wholly owned subsidiaries following Elicio&#x2019;s reverse merger transaction (the &#x201c;Merger&#x201d;) with Angion Biomedica Corp. (&#x201c;Angion&#x201d;) that was completed on June 1, 2023. Terms used but not defined herein shall have the meaning ascribed to them in the Original 10-K.</dei:AmendmentDescription>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-38">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-39">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-40">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-41">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-42">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-43">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-44">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-45">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-46">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-47">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-48">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-49">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-50">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-51">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-52" unitRef="shares">18704798</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-53" unitRef="shares">18704798</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-54">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-55">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-56">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:AuditorName contextRef="c-1" id="f-57">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-58">Tewksbury, MA</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-59">23</dei:AuditorFirmId>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-60">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-61">2025-12-31</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
